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6SUMMARY
Variegate porphyria (VP) is an inherited metabolic disease resulting from the partial 
deﬁ ciency of protoporphyrinogen oxidase (PPOX), the penultimate enzyme in 
the heme biosynthetic pathway. Biochemical abnormalities found in VP patients 
include overproduction and increased excretion of porphyrins and porphyrin 
precursors. Clinical manifestations include acute neurovisceral attacks and cutaneous 
photosensitivity resembling other acute porphyrias.
In the present study, eight mutations (I12T, 78insC, IVS2-2a→c, 338G→C, R152C, 
470A→C, 609delG and L401F) were identiﬁ ed among 22 Finnish VP families by 
direct sequencing of the patients’ genomic DNA. A founder mutation (R152C) was 
detected in 11 families. The outcome of seven mutations was studied by ampliﬁ cation 
and sequencing of the reverse-transcribed total RNA obtained from the patients’ 
EBV-transformed lymphoblast cell lines. One of the mutations (338G→C) showed a 
decrease in the steady-state level of the mutant transcript in the patient’s lymphocytes 
compared with that of the normal allele. For the other six mutations studied, no 
reduction of mRNA level could be demonstrated. The normal allele and six mutants 
were expressed in E. coli and in COS-1-cells. Enzyme activities of all mutated alleles 
I12T, 78insC, IVS2-2a→c, 338G→C, R152C and 470A→C were decreased to 0-5% 
of the wild-type activity both in E. coli and COS-1 cells, conﬁ rming the causality of 
the mutations and the enzymatic defects in this disease.
The mitochondrial targeting of the normal allele and seven PPOX mutants was 
investigated by constructing the corresponding green ﬂ uorescent protein (GFP) 
-fusion proteins and studying their intracellular localization in COS-1 cells. The 
28 amino-terminal amino acids of PPOX contained an independently functioning 
mitochondrial targeting signal. The experiments with amino-terminally truncated 
GFP-fusion peptides revealed that amino acids 25-477 of PPOX contained at least 
one additional mitochondrial targeting signal. A structural model for the interaction 
between the amino-terminal end of PPOX and the putative mitochondrial receptor 
protein Tom20 was constructed. The model suggested that the leucine and isoleucine 
residues Leu8, Ile12 and Leu15 forming the hydrophobic motif LXXXIXXL were 
crucial for the recognition of the targeting signal. Mutants L8Q, I12T and L15Q, 
which disrupted the hydrophobic face of the LXXXIXXL helix, tested the validity 
of the model. Results from the in vitro expression studies and molecular modelling 
were in accordance, supporting the hypothesis that the recognition of mitochondrial 
targeting signal is dependent on hydrophobic interactions between the targeting 
peptide and the mitochondrial receptor.
The clinical and biochemical outcome of 103 Finnish VP patients diagnosed 
between 1966 and 2001 was evaluated. Fifty-two percent of patients had experienced 
clinical symptoms: 40% had photosensitivity, 27% acute attacks and 14% both 
manifestations. The proportion of patients with acute attacks had decreased 
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dramatically from 38% to 14% in patients diagnosed before and after 1980, while the 
prevalence of skin symptoms had decreased only from 45% to 34%. The correlation 
between PPOX genotype and clinical outcome was studied among 90 patients with 
the three most common Finnish mutations I12T, R152C and 338G→C. Patients with 
the I12T mutation experienced no photosensitivity and acute attacks were rare (8%). 
Therefore, the occurrence of photosensitivity was lower in the I12T group than in 
the R152C group (p=0.001), while no signiﬁ cant differences between the R152C and 
338G→C groups could be observed. Biochemical abnormalities were signiﬁ cantly 
milder, suggesting a milder form of the disease in patients with the I12T mutation. 
In all VP patients, normal excretion of faecal protoporphyrin measured in adulthood 
predicted freedom from both skin symptoms and acute attacks. The most valuable 
test predicting an increased risk of symptoms was urinary coproporphyrin, but only 
a substantially increased excretion exceeding 1000 nmol/d was associated with an 
increased risk of skin symptoms and acute attacks. All patients with an excretion of 
more than 1000 nmol/d experienced skin symptoms, acute attacks, or both.  
As a result of this study, DNA diagnostics of VP is now available for 20 of the 
22 known Finnish VP families, where the mutation was detected. The sensitivity 
and speciﬁ city of the biochemical screening for VP were studied among 38 family 
members, for whom the results of both biochemical testing and mutation analysis 
were available. The sensitivity of urinary and faecal coproporphyrin analysis was 
48% and 52%, respectively. The sensitivity of urinary uroporphyrin analysis was 
71% and that for faecal protoporphyrin was 77%. Plasma ﬂ uorescence was sensitive 
in symptomatic patients even in remission but resulted in false-negatives in four 
symptom-free patients with normal excretion of porphyrins in urine. In our series of 
mutation screening, new symptom-free patients could be identiﬁ ed, demonstrating 
that DNA analysis is the only reliable method to screen symptom-free patients in 
remission. 
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9ABBREVIATIONS
aa  amino acid
AIP  acute intermittent porphyria
ALA  5-aminolevulinic acid
ALAS 5-aminolevulinic acid synthase
ALAS1 housekeeping 5-aminolevulinic acid synthase
ALAS2 erythroid-speciﬁ c 5-aminolevulinic acid synthase
bp  base pair
cDNA complementary deoxyribonucleic acid
COS-1 simian virus 40-transformed monkey kidney cell line
CYP  cytochrome P-450
DNA   deoxyribonucleic acid
GFP  green ﬂ uorescent protein
kb  kilobase
kD  kilodalton
mRNA messenger ribonucleic acid
PBG  porphobilinogen
PBGD porphobilinogen deaminase
PCR  polymerase chain reaction
PPOX protoporphyrinogen oxidase
RNA  ribonucleic acid
VP  variegate porphyria
Amino acids are abbreviated by either one or three letter codes and nucleotides by 
one letter code.
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INTRODUCTION
The porphyrias are inherited disorders caused by a partial deﬁ ciency of one of the 
eight enzymes in the heme biosynthetic pathway. Heme is synthesised in most if not 
all cells and is an important constituent of the cellular hemoproteins responsible for 
such essential functions as the transport and storage of oxygen (e.g. hemoglobin, 
myoglobin), electron transport (e.g. respiratory cytochromes) and oxidation-
reduction reactions (e.g. the cytochrome P450 enzymes). Heme is also utilized for 
other important cellular hemoproteins, such as catalase, peroxidase, tryptophan 
pyrrolase, prostaglandin endoperoxide synthase, indoleamine 2,3-dioxygenase and 
guanylate cyclase.
Variegate porphyria (VP) results from a defect in protoporphyrinogen oxidase 
(PPOX), the penultimate enzyme in heme biosynthesis, which catalyses the 
oxidation of protoporphyrinogen IX to protoporphyrin IX in the inner membrane 
of the mitochondrion. The biochemical abnormalities found in VP patients include 
overproduction and increased excretion of porphyrins and porphyrin precursors. VP 
can present with acute neurovisceral symptoms, photosensitivity, or both. The acute 
symptoms are indistinguishable from other acute porphyrias and include abdominal 
pain, vomiting, constipation, hypertension, tachycardia and peripheral neuropathy. 
Skin manifestations, which include increased skin fragility, vesicles, bullae, 
erosions, milia, hyperpigmentation and hypertrichosis in sun-exposed areas, manifest 
independently of acute attacks. 
The clinical and biochemical picture of VP was ﬁ rst described in 1937. Despite 
intensive research in the ﬁ eld of porphyrias since the establishment of the heme 
biosynthetic pathway in the 1950s, the pathogenetic mechanisms of VP, together 
with other porphyrias, are poorly understood. The development of recombinant 
DNA techniques in the 1980s and the cloning of the PPOX gene in the 1990s have 
facilitated research of the disease mechanisms at the molecular level. The aim of this 
study was to identify the gene defects in Finnish VP families and develop methods 
for DNA diagnostics in these patients. The effects of the mutations on mitochondrial 
transport and enzymatic function of PPOX were studied. The clinical and biochemical 
outcome of patients was investigated based on follow-up from 1966 to 2001, and the 
correlation between PPOX genotype and VP phenotype was evaluated.
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1. Heme biosynthesis
The biosynthesis of one molecule of heme requires eight molecules of glycine 
and eight molecules of succinyl CoA. The ﬁ rst and last three enzymes in the heme 
biosynthetic pathway are located in the mitochondrion, whereas the other four 
are in the cytosol (Figure 1). The ﬁ rst enzyme, 5-aminolevulinic acid synthase 
(ALAS), catalyses the condensation of glycine, activated by pyridoxal phosphate 
and succinyl coenzyme A, to form aminolevulinic acid (ALA). In the second step, 
aminolevulinate dehydratase catalyses the condensation of two molecules of ALA to 
form porphobilinogen (PBG). 
Porphobilinogen deaminase (PBGD, also known as hydroxymethylbilane 
synthase or uroporphyrinogen-I synthase) catalyses the head-to-tail condensation 
of four PBG molecules by a series of deaminations to form the linear tetrapyrrole 
hydroxymethylbilane (HMB). Uroporphyrinogen-III synthase catalyses the 
rearrangement and rapid cyclization of HMB to form the asymmetric octacarboxylate 
porphyrinogen uroporphyrinogen III. In the absence of uroporphyrinogen-III 
synthase, HMB may non-enzymatically close to form uroporphyrinogen I, which is 
normally present in only minute amounts and cannot convert to heme.
The ﬁ fth enzyme in the pathway, uroporphyrinogen decarboxylase catalyses the 
sequential removal of the four carboxylic groups of the acetic acid side chains in 
uroporphyrinogen to yield coproporphyrinogen. This compound then enters the 
mitochondrion, where coproporphyrinogen oxidase catalyses the decarboxylation 
of two of the four propionic groups in the presence of oxygen to form the two vinyl 
groups of protoporphyrinogen IX. 
In the seventh step, protoporphyrinogen oxidase (PPOX, [E.C.1.3.3.4.]) oxidizes 
protoporphyrinogen IX to protoporphyrin IX by the removal of six hydrogen atoms. 
Protoporphyrinogen oxidation also occurs non-enzymatically at an appreciable rate. 
Finally, ferrous iron (Fe2+) is inserted into protoporphyrin IX to form heme in a 
reaction catalysed by ferrochelatase (also known as heme synthase).
About 85% of the heme is synthesized in erythroid cells, where the majority is 
used for hemoglobin formation (Berk et al. 1976). Most of the remainder is produced 
in the liver, where 65% is utilized for the formation of the microsomal cytochrome 
P450 enzymes, 8% for the formation of cytochrome b
5
, about 15% for the synthesis 
of peroxisomal catalase and 6% for other mitochondrial cytochromes (Sassa and 
Kappas 1981). The heme biosynthesis is regulated by housekeeping and erythroid-
speciﬁ c ALAS isozymes ALAS1 and ALAS2, respectively, which are encoded by 
separate genes (Bishop 1990). In the liver, heme represses the synthesis of ALAS1 
mRNA at both transcriptional and translational levels (Hamilton et al. 1991) and 
inhibits its transfer from the cytosol into mitochondria (Ades and Harpe 1981). The 
12
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activity of this enzyme can be induced by various drugs, alcohol, steroids and many 
other chemicals, and reduced by e.g. glucose. 
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In erythroid cells, the regulation of heme synthesis differs from that in the hepatic 
cells. ALAS2 is not inducible by drugs that induce ALAS1 (Wada et al. 1967), and 
it is not regulated by feedback repression by heme (Sassa 1976; Fujita et al. 1991). 
Unlike in the liver, heme stimulates hemoglobin synthesis in erythroid cells (Ross 
and Sautner 1976; Dabney and Beaudet 1977) and increases the levels of ALAS2, 
aminolevulinate dehydratase, PBGD and Fe incorporation into heme (Granick and 
Sassa 1978). Ferrochelatase may also play a role in controlling the rate of heme 
formation in erythroid cells and become rate-limiting in these cells when the enzyme 
is partially defective (Anderson et al. 2001).
Heme degradation starts with the reductive breakdown of the heme macrocycle 
into carbon monoxide, Fe2+ and biliverdin in a reaction catalysed by heme oxygenase 
(Tenhunen et al. 1968). Heme oxygenase exists in two isoforms, heme oxygenase 1, 
which is inducible by stressors including cytokines, intake of heavy metals, hypoxia 
and oxygen-free radicals, and heme oxygenase 2, which is constitutive and non-
inducible (Shibahara et al. 1985; Maines et al. 1986). Biliverdin reductase transforms 
biliverdin into the toxic and highly insoluble compound bilirubin in mammals but 
not in most non-mammalian invertebrates. Bilirubin is conjugated with glucuronic 
acid to form a more soluble bilirubin glucuronide, which is excreted in bile (O’Carra 
1975). Since bilirubin is normally produced in humans at a rate of approximately 5 
to 8 µmol bilirubin/kg body weight/day (Berk et al. 1974), it can be estimated that 
the daily ALA requirement for heme biosynthesis is 54 mg in hepatic and 304 mg in 
erythroid tissues (Anderson et al. 2001).
2. The porphyrias
The porphyrias are inherited or acquired disorders of speciﬁ c enzymes in the heme 
biosynthetic pathway. Eight enzymes are involved in the synthesis of heme and all of 
these enzymes and their genes have been thoroughly characterized. A partial defect 
in seven of them is associated with a speciﬁ c porphyria; a defect in ALAS2 results 
in X-chromosome-linked sideroblastic anaemia (Figure 2). Most of the porphyrias 
are inherited as an autosomal dominant trait, but ALA-dehydratase deﬁ ciency and 
congenital erythropoietic porphyria demonstrate an autosomal recessive inheritance. 
Porphyria cutanea tarda can be either sporadic (type I) or familial (types II and 
III). Hepatoerythropoietic porphyria is a rare homozygous form of the familial 
type of porphyria cutanea tarda. The porphyrias are classiﬁ ed as either hepatic or 
erythropoietic depending on the primary site of overproduction and accumulation 
of the porphyrin precursor or porphyrin (Table 1). The hepatic porphyrias manifest 
usually as neurovisceral disorders, including abdominal pain, neuropathy and 
mental disturbances, whereas the erythropoietic porphyrias characteristically cause 
photosensitivity and disrupted erythropoiesis. 
14
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3. Variegate porphyria (VP)
3.1. History and prevalence
The clinical and biochemical picture of VP was ﬁ rst described by van der Bergh 
and Grotepass in 1937 (van der Bergh and Grotepass 1937). Following the ﬁ rst 
South African report in 1945 (Barnes 1945), case reports have been published with 
increasing frequency and a great amount of work was carried out to identify affected 
subjects and to classify the disease as a separate entity. The prevalence of VP is 
exceptionally high in the South African Afrikaans-speaking population (1:300) (Dean 
1969). There, the history of VP can be traced back to the marriage of a Dutch couple 
in the Cape of Good Hope in 1688, and the R59W mutation identiﬁ ed from the family 
members has become enriched within the population of Dutch origin (Meissner et al. 
1996; Warnich et al. 1996). As many as 20 000 South Africans may carry this trait 
due to the founder mutation. In Finland, the prevalence of VP has been estimated to 
be 1.3:100 000 (Mustajoki 1980), as compared with 0.5:100 000 reported in Great 
Aminolevulinate dehydratase
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synthase
Aminolevulinate
dehydratase
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deaminase
Uroporphyrinogen III
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Figure 2. Heme biosynthesis and porphyrias. The enzymatic block is shown on the right 
panel and the associated disease on the left. 
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Britain (Elder et al. 1997) or 1:100 000 reported in Sweden (Wiman 2003). VP is 
the second most common porphyria in Finland after AIP, which has a prevalence of 
approximately 3:100 000 (Kauppinen and von und zu Fraunberg 2002). Porphyria 
cutanea tarda and erythropoietic protoporphyria are less common in Finland, with 
prevalences of 1:100 000 and 0.6:100 000, respectively (K. Timonen, personal 
communication), in contrast to most other countries, where porphyria cutanea tarda 
predominates (Anderson et al. 2001). VP has been termed the “Royal Malady” since 
some British royalty have been suggested to have had this condition (Macalpine 
et al. 1968). These suggestions are not very reliable, though, as they are based on 
retrospective analysis of rather unspeciﬁ c symptoms without proper biochemical 
conﬁ rmation. Synonyms for VP include porphyria variegata, protocoproporphyria 
and South African genetic porphyria.
3.2. Clinical Þ ndings
3.2.1. Skin symptoms
VP can present with neurological manifestations, photosensitivity, or both – hence 
it was termed “variegate”. Skin manifestations often occur apart from neurovisceral 
symptoms and are usually chronic in nature. They are often indistinguishable from 
those seen in porphyria cutanea tarda and hereditary coproporphyria, and include 
increased skin fragility on sun-exposed areas, most frequently on the backs of the 
hands (Day 1986). Even minor trauma results in the epidermis becoming detached 
from the dermis, followed by erosions and blisters (Figure 3A) (Timonen et al. 1990b). 
These lesions heal slowly, especially in the presence of secondary infection, and often 
result in scars, which may be pigmented. Hypertrichosis and hyperpigmentation are 
fairly common on facial skin (Day 1986).
Table 1. Classiﬁ cation of porphyrias.*
Classiﬁ cation Principal symptomology
Erythropoietic
Congenital erythropoietic porphyria Photosensitivity
Erythropoietic protoporphyria Photosensitivity
Hepatic
Aminolevulinate dehydratase 
deﬁ ciency porphyria
Chronic neurological symptoms
Acute intermittent porphyria Acute attacks
Hereditary coproporphyria Acute attacks and/or photosensitivity
Variegate porphyria Acute attacks and/or photosensitivity
Porphyria cutanea tarda Photosensitivity
Hepatoerythropoietic porphyria Photosensitivity
*Adapted from Anderson et al. (2001).
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Histopathological changes in VP are identical to those of porphyria cutanea tarda 
and hereditary coproporphyria and include homogenous periodic acid-Schiff stain- 
positive thickening and immunoglobulin G deposition in superﬁ cial dermal vessel 
walls (Figure 3B) (Timonen et al. 1990b). The immunoglobulins apparently represent 
circulating proteins, and their deposition in the vessel wall is probably a result of 
phototoxic damage to the vessel walls (Cormane et al. 1971; Epstein et al. 1973). 
The changes are more prominent in sun-exposed areas, but slight changes can also be 
detected in sun-protected areas, indicating that porphyrins may induce microscopic 
changes in the vessels with only minimal light exposure (Timonen et al. 1990b).
Three decades ago, the prevalence of skin symptoms was 70-80% in South Africa, 
where the disease is common (Eales et al. 1980), while in Finland less than half of 
the patients experienced only mild skin fragility (Mustajoki and Koskelo 1976). 
This lower frequency of skin symptoms at northern latitudes probably reﬂ ects the 
absence of chronic exposure to strong sunlight (Muhlbauer et al. 1982), but recent 
South African studies also report a lower frequency (38%) of skin symptoms (R. Hift, 
personal communication).
3.2.2. Acute attacks
Acute attacks of VP are identical to those of other acute porphyrias. All symptoms 
during the attack are suggested to be due either to autonomic or peripheral neuropathy 
A B
Figure 3. A Erosions and superﬁ cial scars on the skin of the hand of a VP patient. B Thickening 
of the superﬁ cial dermal vessel walls in the sun-exposed skin of a 80-year-old patient with 
skin symptoms (periodic acid-Schiff staining; x 120). (Courtesy of Dr. K.Timonen)
17
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or to CNS involvement (Crimlisk 1997). Symptoms of autonomic neuropathy include 
abdominal pain, which is the key symptom, hypertension, tachycardia, vomiting and 
constipation (Eales et al. 1980; Mustajoki 1980; Kirsch et al. 1998). The sensory 
neuropathies usually manifest as pain in the extremities or in the back, and motor 
neuropathy as variable pattern symmetrical weakness that may progress to paralysis 
and respiratory failure requiring prolonged mechanical ventilation (Ridley 1969). 
Peripheral neuropathy has become rare during the last decades due to early treatment 
of all acute attacks with heme arginate (Mustajoki and Nordmann 1993) and improved 
counselling (Kauppinen and Mustajoki 1992). The most common sign of CNS 
involvement is psycho-organic syndrome with anxiety, depression, hallucinations, 
delirium and dementia (Crimlisk 1997). Hyponatremia with evidence of sodium 
depletion or inappropriate ADH secretion can occur during acute attacks (Eales 
1963) and is suggested to be due to hypothalamic involvement (Suarez et al. 1997). 
Epileptic seizures are known to be present in 5-20% of acute attacks and are often 
associated with hyponatremia (Stein and Tschudy 1970; Bylesjo et al. 1996). Urine 
can be dark in colour because PBG is auto-oxidized to porphobilin and porphyrins are 
formed non-enzymatically (Bissell 1982) (Table 2). 
Peripheral nerve conduction studies show a primarily axonal degeneration rather 
than demyelinization (Flugel and Druschky 1977; Wochnik-Dyjas et al. 1978), and 
these ﬁ ndings are supported by histological studies (Cavanagh and Mellick 1965). 
Slight peripheral neuropathy may be demonstrable in the latent form of acute 
porphyria and even in patients who have never been symptomatic (Mustajoki and 
Seppäläinen 1975; Kochar et al. 2000). 
Table 2. Clinical features of an acute attack of VP
Mustajoki
1980
Eales
1980
Kirsch et al.
1996
n=18 n=100 n=23
(%) (%) (%)
Abdominal pain 95 98 95
Tachycardia 90 80 35
Dark or red urine 80 
Constipation 80 60 25
Muscle weakness 80 60* 10*
Psychiatric symptoms 80
Abdominal tenderness 80
Non abdominal pain 70
Vomiting 65 75 60
Hypertension 60 60 55
Respiratory muscle paralysis 40
Objective sensory disturbances 40
Epileptic seizures 25 25 5
Cranial nerve abnormalities 20 20 5
Adapted from Eales et al. (1980); Mustajoki (1980); Kirsch et al. (1998)
* recorded as neuropathy without further deﬁ nition. 
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Three decades ago, 17-38% of VP patients experienced acute attacks (Eales et al. 
1980; Mustajoki 1980; Muhlbauer et al. 1982), but milder symptoms of porphyria are 
more common, occurring in 30-40% of patients (Kauppinen and Mustajoki 1992). 
Symptoms rarely occur before puberty and more than 50% of carriers of the affected 
gene probably remain symptom-free throughout their lives (Mustajoki 1980).
Acute attacks are often induced by various exogeneous and endogeneous 
precipitating factors such as drugs (for an extensive list of potentially safe and unsafe 
drugs, see http://www.uq.edu.au/porphyria), alcohol (Thunell et al. 1992), infection 
(Paxton et al. 1974), fasting (Perlroth et al. 1968; Quiroz-Kendall et al. 1983) or the 
menstrual cycle (Tschudy et al. 1975; Mustajoki and Koskelo 1976; Kauppinen and 
Mustajoki 1992). Most precipitating factors have the capacity to induce production 
of hepatic cytochrome P450 enzymes, which may cause heme depletion and 
secondary ALAS1 activation. Direct transcriptional activation of ALAS1 via drug-
responsive enhancer sequences has also been reported (Fraser et al. 2002). ALAS1 
induction leads to an increased synthesis and accumulation of heme biosynthetic 
pathway intermediates in the presence of the enzymatic blockade in VP. Individual 
susceptibility to clinical manifestations is likely determined by other genetic factors 
(Grandchamp 1998). Sulphonamide antibiotics exert their harmful effects by a 
different mechanism, probably via PBGD inhibition (Peters et al. 1980; Tishler 
1999), since they apparently do not induce production of ALAS1 and cytochrome 
P450 enzymes. 
VP patients occasionally present with chronic liver abnormalities including mild 
inﬂ ammation and ﬁ brosis of the portal tracts and iron deposits (McGrath et al. 1984; 
Mascaro et al. 1985). Increased risk of hepatocellular carcinoma has been reported 
among patients with VP, as in AIP and porphyria cutanea tarda (Berman and Braun 
1962; Kauppinen and Mustajoki 1988; Tidman et al. 1989; Germanaud et al. 1994; 
Andant et al. 1998).
3.2.3. Homozygous VP
The ﬁ rst cases of homozygous VP were described in 1984, and since then, 14 
homozygous patients have been reported world-wide (Kordac et al. 1985; Murphy et 
al. 1986; Mustajoki et al. 1987; Coakley et al. 1990; Norris et al. 1990; Gandolfo et 
al. 1991; Hift et al. 1993; Roberts et al. 1998; Corrigall et al. 2000). Six of the patients 
were heteroallelic (Meissner et al. 1996; Frank et al. 1998d; Roberts et al. 1998; 
Palmer et al. 2001) and two homoallelic, with a varying amount of residual PPOX 
activity in vitro (9-25%) (Roberts et al. 1998).
In the homozygous form of VP, patients have markedly reduced PPOX activity 
in the lymphocytes or cultured ﬁ broblasts (0-20% of normal) (Mustajoki et al. 
1987; Norris et al. 1990) and severe clinical manifestations with onset in childhood 
(Hift et al. 1993). Severe photosensitivity is accompanied in 50-70% of patients 
by neurological symptoms, convulsions and developmental disturbances. Growth 
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retardation in infancy or childhood has been reported in 80% and mental retardation 
in 50% of  patients (Table 3).
3.3. Biochemical Þ ndings
Biochemical abnormalities found in VP patients include overproduction and 
increased excretion of porphyrins and porphyrin precursors. Routes of excretion are 
determined in part by the degree of porphyrin solubility in water, which is increased 
in the presence of carboxylic acid side chains. Uroporphyrin is the most water-soluble 
of the porphyrins derived from the heme biosynthetic pathway, and protoporphyrin 
the least soluble. Hence, uroporphyrin is excreted predominantly in urine and 
coproporphyrin mostly in urine but partly in bile, whereas protoporphyrin is so 
hydrophobic that it is excreted only in bile and faeces (Anderson et al. 2001). Much 
of the protoporphyrinogen IX that accumulates in VP undergoes auto-oxidation to 
protoporphyrin IX before excretion.
When VP is clinically active, faecal copro- and protoporphyrin and urinary uro- 
and coproporphyrin are elevated. Of the urinary coproporphyrin, 70-90% is type 
III isoform, as in AIP (Mustajoki 1980; R. Kauppinen, personal communication). 
The proportion of coproporphyrin III in faeces is 60-85% in VP (Mustajoki 1980), 
which is slightly less than the 30-60% encountered in AIP, but due to wide inter-
individual variation, the fractionation should not be used to distinguish AIP and 
VP (R. Kauppinen, personal communication). The concerted excretion of proto- 
and coproporphyrin to bile could be explained by the close association between 
Table 3. Comparison of the clinical features of homozygous and heterozygous VP.
    Homozygous VP Heterozygous VP
   (n / total) (%) (%)
Age at onset <18 months after puberty
Developmental delay 5 / 5 100
Hand deformities 9 / 9 100
Photosensitivity 11 / 12 92 38-70
Growth retardation 7 / 9 78 
Fits 8 / 11 73
Retarded bone age 2 / 3 67
Nystagmus 5 / 10 50
Mental retardation 6 / 13 46
Acute attacks 2 / 12 17 17-38
Death 1 / 9 11 
Adapted from Kordac et al. (1985); Murphy et al. (1986); Mustajoki et al. (1987); Coakley 
et al. (1990); Norris et al. (1990); Gandolfo et al. (1991); Hift et al. (1993); Roberts et al. 
(1998); Corrigall et al. (2000).
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PPOX in the inner mitochondrial membrane and coproporphyrinogen oxidase in 
the intermembrane space (Deybach et al. 1985). The plasma ﬂ uorescence spectrum 
shows a VP-speciﬁ c emission maximum at 626 nm (Enriquez de Salamanca et al. 
1993; Long et al. 1993; Da Silva et al. 1995).  Biliary porphyrins are also increased 
(Logan et al. 1991), suggested to lead to the formation of gallstones, which contain 
protoporphyrin (Herrick et al. 1991).
Urinary PBG and ALA are increased during an acute attack but may be normal 
or only slightly increased during remission (Meissner et al. 1993). In heterozygous 
VP patients, half-normal activity of PPOX can be demonstrated in cultured skin 
ﬁ broblasts, peripheral leucocytes and lymphocytes, cultured lymphoblasts and 
hepatocytes (Brenner and Bloomer 1980; Deybach et al. 1981; Viljoen et al. 1983; 
Meissner et al. 1986; Li et al. 1989). In the homozygous form of VP, patients have 
an 8- to 15-fold increase in erythrocyte protoporphyrin levels, 60-80% of which is 
zinc-bound (Kordac et al. 1985; Murphy et al. 1986; Mustajoki et al. 1987). A less 
marked 1.5–fold increase has been reported in heterozygous cases (Mustajoki 1980). 
A distinguishing feature in VP is the presence, especially in the bile and faeces, but 
also in the plasma and occasionally the urine, of hydrophilic porphyrin-peptide 
complexes termed X-porphyrins (Rimington et al. 1968; Smith et al. 1968, 1969; 
Elder et al. 1974). 
3.4. Pathogenesis
3.4.1. Acute attacks
The acute symptoms in VP are identical to those in other acute porphyrias and result 
from neurological dysfunction. The direct or indirect induction of ALAS1, which 
is the rate-limiting enzyme of the pathway, plays a key role in the pathogenesis of 
acute attacks. If heme requirements in the cell are increased, for instance by increased 
turnover of certain hemoproteins, ALAS is induced (Meyer et al. 1998) and the 
normal activity of PBGD becomes the rate-limiting step (Elder et al. 1976), resulting 
in the accumulation of precursors ALA and PBG. Decreased PBGD activities (50-
75% of normal) have also been reported in VP patients’ lymphocytes (Meissner et al. 
1993; Weinlich et al. 2001), and this inhibition is presumably consequent upon the 
accumulation of intracellular protoporphyrinogen (Meissner et al. 1993). 
Neurotoxicity of porphyrin precursors
According to the leading hypothesis, neurotoxicity of ALA or PBG may cause 
neuropathy during the acute attacks, although the mechanism of neural damage is 
poorly understood (Bonkowsky and Schady 1982; Yeung Laiwah et al. 1987). The 
levels of ALA and PBG are virtually never normal during an acute attack. These 
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precursors most likely originate from the liver, where ALAS1 is induced by factors 
known to provoke acute porphyria, such as certain drugs and hormones (Anderson et 
al. 2001).  
Current theories of the porphyric neuropathy implicate ALA as a potential 
neurotoxin. ALA can enter most tissues readily and undergo metal-catalysed 
oxidation, promote lipid peroxidation and mediate oxidative damage through release 
of iron from ferritin in the liver (Oteiza et al. 1995). ALA is also structurally similar 
to γ-aminobutyric acid (GABA) and can interact with GABA receptors, which could 
explain the CNS involvement but not the neuronal damage (Müller and Snyder 1977; 
Brennan and Cantrill 1979). 
In vitro, ALA caused misﬁ ring of electrically stimulated neurons of crayﬁ sh 
(Bonkowsky and Schady 1982) and death of cultured neuronal and glial cells of 
chick embryos (Percy and Lamm 1981). In vivo, acute administration of ALA did 
not provoke any symptoms in a volunteer (Mustajoki et al. 1992b) or AIP patients 
(Dowdle et al. 1968; Meyer et al. 1972; Shimizu et al. 1978), indicating that a 
more prolonged exposure is required to develop acute symptoms of porphyria. In 
human, the blood-brain barrier (BBB) is only weakly permeable to ALA, and the 
concentrations detected in the cerebrospinal ﬂ uid (CSF) are only 2-3% of blood 
levels (Bonkowsky et al. 1971; Percy and Shanley 1977; Gorchein and Webber 
1987), which may be insufﬁ cient to explain the CNS symptoms (Meyer et al. 1998). 
However, the peripheral nerves are not protected by the blood-brain barrier and are 
exposed to levels of ALA comparable with those in blood (Meyer et al. 1998).
Heme deﬁ ciency in nerve cells
An alternative hypothesis suggests that depletion of heme in the nerve cells could 
impair the functions of several hemoproteins, such as microsomal cytochromes, which 
are required for oxidative phosphorylation or to catalyse mixed-function oxidation 
(Watson 1975). A further suggestion is that heme deﬁ ciency in the liver might dispose 
to unsaturation of hepatic tryptophan pyrrolase and lead to increased tryptophan 
delivery to the central nervous system (Litman and Correia 1985). Disturbance of the 
serotonergic system could explain the autonomic dysfunction during an acute attack 
(Meyer et al. 1998). 
Depletion of essential substrates or cofactors
The increased activity of ALAS1 may also lead to the depletion of essential substrates 
or cofactors such as pyridoxal phosphate (PLP), zinc or glycine. Neuropathic 
manifestations of pyridoxal phosphate deﬁ ciency resemble acute porphyrias, and 
there is evidence of low pyridoxal phosphate status in some AIP patients (Cavanagh 
and Ridley 1967; Hamfelt and Wetterberg 1969). 
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Genetic factors modifying liver metabolism
Heme biosynthesis and degradation are closely interrelated to the function of 
cytochrome P450 enzymes. Several polymorphisms in cytochrome P450 enzymes 
exist (van der Weide and Steijns 1999), and these genes are good candidates for 
modifying porphyrin metabolism and phenotype. A diminished supply of heme 
may lead to insufﬁ cient function of P450-mediated reactions in VP patients: the 
metabolism of antipyrine and aminopyrine is prolonged (Birnie et al. 1987), which 
can be reversed using exogenous heme administration (Tokola et al. 1988; Mustajoki 
et al. 1992a). In addition, the activity of normally functioning P450 enzymes can be 
further induced by exogenous heme administration (Mustajoki et al. 1994). The effect 
is isozyme-speciﬁ c in both VP patients and healthy subjects, and thus, exogenous 
heme can accelerate the reactions mediated by the cytochrome isozymes CYP2D6 
and CYP3A4 but not by CYP1A2 and CYP2A6 (Mustajoki et al. 1994). In a rat 
porphyria cutanea tarda model, CYP3A induction was shown to attenuate the hepatic 
accumulation and urinary excretion of uro- and heptacarboxylporphyrins (Franklin et 
al. 2000). 
The removal of excess porphyrins and their precursors from the liver could be at 
least partly due to ATP-binding cassette (ABC) efﬂ ux proteins, which can transport 
virtually any class of substrate, including drugs, steroids, polysaccharides, amino 
acids and peptides, across membranes (Kerb et al. 2001). MRP2 is an ABC efﬂ ux 
protein located at the apical surface of the hepatocytes and epithelial cells of the 
gastrointestinal tract and kidney (Figure 4) (Cole et al. 1992). A defect in the MRP2 
gene has been linked to the Dubin-Johnson syndrome, which is characterized by 
impaired secretion of anionic conjugates from hepatocytes into the bile and conjugated 
hyperbilirubinemia (Dubin and Johnson 1954; Kartenbeck et al. 1996; Wada et al. 
1998). In Dubin-Johnson syndrome, the excretion of coproporphyrin in urine was 
increased 1.5- to 2-fold (Koskelo and Mustajoki 1980), and the proportion of isomer 
I in homozygotes and heterozygotes was 88.9% and 31.6%, respectively, whereas 
in normal individuals, it was 24.8% (Wolkoff et al. 1973). Hence, polymorphisms 
in the MRP2 gene may well contribute to the accumulation of porphyrins and their 
precursors in hepatocytes and predispose to acute attacks.
P-glycoprotein (PGP) is another ABC efﬂ ux protein, which is capable of clearing 
cells of cytotoxic substances such as several anticancer drugs and other therapeutic 
agents (Gros et al. 1986; Fromm 2000). P-glycoprotein is coded by the multi-drug 
resistance gene 1 (MDR1) and expressed at the apical surface of hepatocytes, where it 
contributes to the drug efﬂ ux to bile. The repression of P-glycoprotein in MDR1(-/-) 
mice has been shown to increase CYP3A4-mediated drug metabolism in the liver 1.5- 
to 1.9-fold by increasing substrate availability (Lan et al. 2000). MDR1 deﬁ ciency 
could be postulated to lead to an increasing demand for CYP450 hemeoproteins and, 
consequently, heme depletion and ALAS1 induction. In addition, the removal of 
porphyrins and their precursors from hepatocytes could be impaired, leading to their 
accumulation in the liver. Several polymorphisms in the MDR1 gene exist (Kerb et al. 
2001), but only the 3435C→T polymorphism has been shown to be associated with 
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decreased P-glycoprotein activity (Hoffmeyer et al. 2000). Since it is located at a non-
coding non-promoter region, it is unlikely to inﬂ uence P-glycoprotein expression, but 
may be linked to other as yet unidentiﬁ ed modiﬁ er loci.
Mouse models of acute porphyrias
Recently, a mouse model of VP with the R59W mutations has been developed in 
C57/BL6 mice using targeted gene replacement (Medlock et al. 2002). Hepatic 
PPOX activity was reduced by approximately 50% in heterozygous mice. Urine and 
faecal samples from these mice demonstrated elevated concentrations of porphyrins 
and porphyrin precursors resembling the biochemical characteristics of human VP. 
ALA feeding of these mice resulted in an accentuated pattern of porphyrin excretion 
characteristic of VP, and urinary ALA and PBG were increased signiﬁ cantly. This 
suggests that the mice present a good model of the biochemical abnormalities in VP, 
but the clinical phenotypes have not yet been characterized (Medlock et al. 2002). 
A PBGD-deﬁ cient mouse has been generated to gain insight into the 
pathophysiological mechanisms of porphyric neuropathy in AIP (Lindberg et al. 
1996, 1999). Compound heterozygous mice T1/T2 (-/-) with a loss-of-function allele 
(T2) and a partial disruption of PBGD (T1) are viable and have 30% of normal PBGD 
activity. The PBGD-deﬁ cient T1/T2 (-/-) mice have normal levels of urinary ALA 
and PBG, but after phenobarbital treatment, the plasma levels and urinary excretion 
of ALA are massively increased, resembling levels found during an acute attack in 
man. Behavioural studies with the mice suggest that heme deﬁ ciency and consequent 
MRP2 PGP
Bile canaliculi
Hepatocyte
PGP
Apical surface
Basolateral surface
CYP3A4
A B
Figure 4. A Localization of drug transport proteins in liver cells. B Pathway of substrates 
common for P-glycoprotein and CYP3A4. MRP2, Multidrug resistance protein 2; PGP, P-
glycoprotein. Adapted from Borst et al. (1999); Lan et al. (2000).
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dysfunction of hemoproteins cause chronic and progressive neuropathy, leading to 
impairment of motor co-ordination and muscle weakness (Lindberg et al. 1999). 
Hence, the mouse model resembles the chronic neuropathy occasionally seen in AIP 
and VP patients, but provides no information about pathogenetic mechanisms of an 
acute attack.
3.4.2. Photosensitivity
Most of the knowledge about the chronic type of cutaneous VP lesions comes from 
studies of the identical lesions in porphyria cutanea tarda. The proposed pathogenetic 
mechanism is that excess porphyrins in plasma and/or skin interact with light energy, 
inducing a phototoxic reaction and tissue damage (Day 1986). Absorption of a 
photon of near ultraviolet light (~400 nm) raises the porphyrin to its singlet-excited 
state, which may be converted to the metastable triplet-excited state. In the singlet 
state, the excited porphyrins may directly react with biomolecular targets, whereas 
the oxidative damage of the triplet-state porphyrin is mediated by the production of 
singlet-oxygen, destructive for most biological systems (Spikes 1975; Bodaness and 
Chan 1977). This event may be accompanied by photoactivation of the complement 
system, which acts synergistically to amplify the tissue damage (Lim et al. 1984; 
Meurer et al. 1985).
The prevailing hypothesis states that the excess porphyrins in the skin of patients 
with cutaneous porphyrias originate from the circulating plasma porphyrins (Day et 
al. 1978; Longas and Poh-Fitzpatrick 1982). In VP, the plasma porphyrins are mostly 
hydrophobic coproporphyrin and protoporphyrin (Poh-Fitzpatrick 1980; Long et al. 
1993). Quantitative thin-layer chromatography did not reveal an association between 
circulating plasma porphyrin levels and cutaneous symptoms in a large series of 
patients with VP and porphyria cutanea tarda (Day et al. 1978). However, frequency 
of cutaneous symptoms has been shown to be positively correlated with urinary 
coproporphyrin levels (Timonen et al. 1990b). 
3.5. Diagnosis
VP should be included whenever AIP or other acute porphyrias are considered as a 
potential cause of acute neurovisceral symptoms. During an acute attack measurement 
of urinary PBG and ALA is essential, and the plasma ﬂ uorescence emission spectrum 
and faecal protoporphyrin measurements can be used to distinguish VP from other 
acute porphyrias (AIP and hereditary coproporphyria). If a patient experiences 
photosensitivity, measurements of the plasma ﬂ uorescence emission spectrum, 
urinary copro- and uroporphyrins and faecal protoporphyrins are indicated and 
distinguish VP from other cutaneous porphyrias (porphyria cutanea tarda, hereditary 
coproporphyria, erythropoietic protoporphyria and congenital erythropoietic 
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porphyria) (Mustajoki 1980; Poh-Fitzpatrick 1980; Timonen et al. 1990b; Da Silva et 
al. 1995). The measurement of PPOX activity in cells that contain mitochondria, such 
as lymphocytes, may provide additional information if other biochemical analyses 
remain inconclusive. The assays for PPOX activity are laborious and not widely 
available. 
3.6. Treatment
Speciﬁ c treatment of acute attacks involves prompt initiation of intravenous heme 
(heme arginate 3 mg/kg daily for 2 to 4 days) and administration of glucose to avoid 
fasting (Watson et al. 1978; Mustajoki et al. 1986; Mustajoki and Nordmann 1993). 
Symptomatic treatment of pain, nausea and electrolyte imbalance is necessary. 
General and supportive measures are also important, including monitoring of 
nutrional status and withdrawal of precipitating factors (Mustajoki and Nordmann 
1993). Heme therapy is the most effective treatment since it represses hepatic ALAS1 
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Figure 5. Faecal excretion of protoporphyrin (solid line) and coproporphyrin (dashed line) 
after administration of heme arginate in a patient with VP in remission. The dotted line gives 
the upper limit of the normal value. Adapted from Mustajoki et al. (1986).
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(Granick et al. 1975; Sassa et al. 1979) and reduces urinary PBG and ALA levels in 
AIP and faecal protoporphyrin and coproporphyrin levels in VP (Bonkowsky et al. 
1971; Mustajoki et al. 1986) (Figure 5).
Heme treatment should be started as early as possible since the clinical response 
depends on the degree of neuronal damage that occurred before the initiation of therapy 
(Mustajoki et al. 1986; Mustajoki and Nordmann 1993). Currently available heme 
preparations for intravenous infusion include hematin (heme hydroxide) (Watson et 
al. 1978; Lamon et al. 1979) and heme arginate (Sievers et al. 1987; Tenhunen et al. 
1987). Heme arginate is preferable as it is more stable and seldom associated with 
phlebitis and coagulopathy, which are common side effects of hematin (Tenhunen 
and Mustajoki 1998). 
The prevention of cutaneous symptoms is difﬁ cult and therapies such as propranolol, 
d-penicillamine, hemodialysis, alkalization of urine, repeated venesections, 
cloroquine and β-carotene are of little or no beneﬁ t (Cramers and Jepsen 1980; 
Kirsch et al. 1998). Heme arginate therapy did not change the photoreactivity of the 
skin or improve skin lesions (Timonen et al. 1990a). Protection from sunlight using 
proper clothing, etc., is the only effective way to avoid cutaneous symptoms.
4. Protoporphyrinogen oxidase (PPOX)
4.1. The PPOX gene
The human PPOX-cDNA was isolated by complementation in vivo of a hemG mutant 
of E. coli (Nishimura et al. 1995), and subsequently, the PPOX gene was mapped 
to chromosome 1q23. The entire coding region for human PPOX was characterized 
(Roberts et al. 1995; Taketani et al. 1995); the gene is 5.5 kb including a 660 bp 
promoter region. The coding sequence is 1431 bp and encodes a 477 amino acid 
polypeptide with a M
r
 of 50.8 kDa (Puy et al. 1996; Dailey and Dailey 1997b) 
(Figure 6). 
The human, mouse and bacterial PPOX amino acid sequences show a high degree 
of homology near the N-terminus of the polypeptide (Nishimura et al. 1995; Dailey 
and Dailey 1998). This area contains a characteristic βαβ dinucleotide-binding motif, 
which is often found within ﬂ avine adenine dinucleotide (FAD) -binding domains 
(Wierenga et al. 1986). Consistent with this ﬁ nding, human PPOX has been shown 
to contain non-covalently bound FAD (Dailey et al. 1995). Northern blot analyses 
from various tissues indicate the presence of a single PPOX transcript of 1.8 kb in 
all tissues (Dailey et al. 1995; Nishimura et al. 1995; Dailey and Dailey 1996). Gel 
ﬁ ltration of the puriﬁ ed protein under non-denaturing conditions suggests that the 
active enzyme functions as a homodimer (Dailey and Dailey 1996).
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4.2. Function and localization of  PPOX
PPOX catalyses the six-electron oxidation of protoporphyrinogen IX to the planar, 
fully conjugated macrocycle protoporphyrin IX in the inner membrane of the 
mitochondrion and requires oxygen for its activity (Dailey 1990). The oxidation 
occurs in three steps, consuming 3 mol of O
2
 and producing 3 mol of H
2
O
2
. 
Dihydroporphyrin and tetrahydroporphyrin intermediates of the reaction are released 
and subsequently rebound by the enzyme for further oxidation to the end product, 
protoporphyrin (Figure 7). 
PPOX acts speciﬁ cally on protoporphyrinogen and does not catalyse the oxidation 
of coproporphyrinogen I, coproporphyrinogen III or uroporphyrinogen I. The 
activity of PPOX can be enhanced by sulfhydryl-reducing agents, like glutathione at 
low concentrations (Poulson 1976). Hemin at concentrations of 50 µM inhibits the 
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Figure 6. Exon/intron organization of the human protoporphyrinogen oxidase gene and 
reported mutations responsible for VP outside Finland (November 2002). Exons are 
indicated by boxes: closed and open boxes represent protein-coding and untranslated 
regions, respectively.
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enzyme activity in a non-competitive and irreversible fashion (Poulson and Polglase 
1975).
PPOX is associated with the lipid bilayer of the inner membrane of the mitochondria 
in eucaryotes (Deybach et al. 1985), with its active site facing the cytosolic side of 
this membrane (Ferreira et al. 1988). The anchoring of PPOX to the inner membrane 
may involve amphipathic helical domains that are responsible for insertion of the 
enzyme into the inner mitochondrial membrane. Another possibility is that PPOX 
is anchored to the inner mitochondrial membrane by a different mechanism, such as 
acylation (Arnould et al. 1999).
PPOX has been postulated to interact with ferrochelatase to channel protoporphyrin, 
and the terminal three enzymes to form an enzyme complex at the inner mitochondrial 
membrane (Ferreira et al. 1988) (Figure 8). The close association of the two enzymes 
would help explain the accumulation of both coproporphyrin and protoporphyrin in 
the excretions of VP patients. Studies with radiolabelled substrates and quantiﬁ cation 
of substrate utilization and product formation have demonstrated, however, that 
substrate channelling between the terminal three enzymes is not obligatory (Proulx 
et al. 1993).
4.3. Mitochondrial targeting of  PPOX
The mitochondrial targeting mechanism of PPOX is currently unknown since the 
gene does not encode typical mitochondrial targeting and import sequences or 
membrane-spanning regions (Puy et al. 1996; Kirsch et al. 1998). The majority of 
proteins destined for import into mitochondria contain a signal sequence in their 
amino terminus that directs them into mitochondria (Pfanner 2000). Signal sequences 
can also be found in the carboxyl terminus of the protein mediating the import in a 
PPH + PPOX6 PPH PPOX6 PPH + PPOX H4 2
PPH PPOX4PPH + PPOX H2 2
PPH + PPOX4
PPH + PPOX2PPH PPOX2
PP + PPOX H2 PP + PPOX
O2 H O2 2
O2 H O2 2
O2H O2 2
Figure 7. Proposed model for the action of PPOX. PPH
6
, protoporphyrinogen IX; PPH
4
, 
tetrahydroprotoporphyrin; PPH
2
, dihydroprotoporphyrin; PPH, protoporphyrin. Adapted 
from Dailey and Dailey (1997b).
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reverse carboxy- to amino-terminal direction (Pfanner et al. 1987; Lee et al. 1999). 
These mitochondrial targeting signals comprise some 20 to 60 amino acid residues 
that have the potential to form amphiphilic α-helices with one hydrophobic and 
one positively charged side (von Heijne 1986; Roise et al. 1988). The presequence 
peptides of different mitochondrial proteins do not show amino acid sequence 
identity but do have characteristic physico-chemical properties. They are enriched in 
positively charged, hydroxylated and hydrophobic residues, have no acidic residues 
and usually are able to form an amphiphilic secondary structure (von Heijne 1986; 
Roise and Schatz 1988).
The amino terminus of PPOX contains a characteristic βαβ dinucleotide-binding 
motif often found within ﬂ avine adenine dinucleotide (FAD) -binding domains 
(Wierenga et al. 1986). The amino terminus is the putative mitochondrial targeting 
domain since it contains three basic residues and no acidic residues, which is 
characteristic for a mitochondrial targeting presequence, and is capable of forming 
an α-helix.
Protein import into mitochondria is mediated by protein assemblies, translocases 
of outer and inner mitochondrial membranes (TOM and TIM, respectively) (for 
review, see Voos et al. (1999); Herrmann and Neupert (2000)) (Figure 9). The N-
terminal targeting signal initially interacts with the general import receptor Tom20, 
which is part of the TOM complex (Ramage et al. 1993; Brix et al. 1997). After 
binding, the polypeptide is allowed to cross the lipid bilayer through the general 
translocation pore formed by receptors Tom22, Tom40 and the intermembrane space 
domains of Tom22 and Tim23 (Schatz and Dobberstein 1996; Neupert 1997; Voos 
Heme
Intermembrane
space
FC Inner membrane
Outer membrane
PPOX
CPO
Coproporphyrinogen III
Protoporphyrinogen IX
Protoporphyrin IX
Figure 8. A proposed model for the terminal three membrane-associated enzymes of the 
heme biosynthetic pathway. CPO copropoprhyrinogen oxidase; PPOX protoporphyrinogen 
oxidase; FC ferrochelatase. Adapted from Ferreira et al. (1988).
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et al. 1999). The preprotein is driven across the inner membrane by the membrane 
potential and the heat shock protein mtHsp70 (Jensen and Johnson 1999). Eventually, 
the presequence is cleaved off by the mitochondrial processing peptidase (MPP) and 
the protein folds into its functional conformation. 
Recently, the NMR structure of rat Tom20 in complex with a mitochondrial 
presequence peptide has been determined, revealing that an amphiphilic α-helical 
structure of presequences is critical for binding to the receptor. The hydrophilic 
residues, including the two positively charged arginines in the presequence, are 
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Figure 9. Transport pathway of an amino terminal presequence-carrying preprotein from the 
cytosol into mitochondria. Preproteins can be inserted into the inner membrane by several 
different pathways: (1) arrest at the level of the TIM23 complex and lateral insertion into the 
lipid bilayer (stop-transfer mechanism); (2) reinsertion into the inner membrane by the Oxa1 
complex; or (3) transfer to the Tim22 complex by the soluble Tim9/Tim10 complex. Adapted 
from Pfanner (2000); Herrmann and Neupert (2000).
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dispensable for binding to Tom20; however the hydrophobic residues are critical 
(Abe et al. 2000). 
The proteins are incorporated into the inner membrane by several different 
pathways. Firstly, proteins can become arrested at the level of the TIM23 complex 
and then laterally inserted into the lipid bilayer (stop-transfer mechanism) (Kaput 
et al. 1982; van Loon and Schatz 1987). Secondly, proteins can be completely 
transported into the matrix from where they reinsert into the inner membrane by 
the Oxa1 complex (Hell et al. 1998). Thirdly, after translocation through the TOM 
complex, a Tim9/Tim10 soluble complex can bind preproteins and transfer them to 
the TIM22 complex, which mediates the insertion of the preproteins into the inner 
membrane (Sirrenberg et al. 1996; Koehler et al. 1998a, 1998b; Sirrenberg et al. 
1998; Adam et al. 1999).
4.4. Mutations causing VP
By November 2002, a total of 102 mutations causing VP had been reported in the 
PPOX gene outside Finland. The mutations are distributed throughout the coding 
region of the PPOX gene, with no exon having >13 or <2 different mutations. No 
mutational hot spots have been identiﬁ ed (Figure 6, Table 4) (Deybach et al. 1996; 
Meissner et al. 1996; Warnich et al. 1996; Frank and Christiano 1997; Lam et al. 
1997, 2001; Corrigall et al. 1998, 2000, 2001; Frank et al. 1998a, 1998b, 1998c, 
1998d, 1998e, 2001a, 2001b; Roberts et al. 1998; Whatley et al. 1999; De Siervi et 
al. 2000a, 2000b; Maeda et al. 2000; Palmer et al. 2001; Donnelly et al. 2002). Of 
the mutations, 36 (35%) are small insertions or deletions, 40 (39%) are missense 
mutations, 15 (15%) change invariant nucleotides at splice sites, 1 (1%) is a gross 
deletion and 10 (10%) produce stop codons.
The effects of 27 PPOX mutations have been analysed in a prokaryotic expression 
system. The South African mutation R59W resulted in a loss of enzyme activity 
(Meissner et al. 1996), as did mutations G40E, L85P, G232R, H281del, V282D, 
L295P, V335G, S350P, L444P and G453V (Morgan et al. 2002). In mutations 
A219KANA, D349A, G358R and A433P found in homozygous VP patients, 9.5-
25% of wild-type activity was preserved (Dailey and Dailey 1997a; Roberts et al. 
1998). The enzyme activities of mutations L15F, R38P, L73P, V84G, D143V, R152C, 
L154P, V158M, R168H, A172V, V290L and G453R ranged from 1% to 9.2% of 
wild-type activity (Morgan et al. 2002). 
In addition to the above-described mutations, several intragenic single nucleotide 
polymorphisms (SNP) have been found in the PPOX gene, both in the translated 
and untranslated regions (Kotze et al. 1998; Whatley et al. 1999). In vitro studies 
using a luciferase assay revealed that a common promoter region polymorphism, 
–1081G→A, resulted in a reduction in transcriptional activity but did not affect the 
clinical expression of the disease (Warnich et al. 2002). 
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Table 4. Reported mutations in the PPOX gene
Mutation Outcome* Reference Mutation Outcome Reference
Exon 2: Intron 6:
1A→G M1V 13 IVS6+1g→c del exon 6 13
1A→C M1L 13 IVS6-1g→c del exon 7 13
3G→C M1I 13 Exon 7:
31G→A G11S 18 657ins12bp A219KANA** 12
45G→C L15F 13,21 657ins12bp A219KASA** 20
59A→C H20P 2 672G→A W224X 13
Exon 3: 694G→C G232R 3,13
113G→C R38P 13 695G→C G232R 13
119G→A G40E 13 745insC stop +31 3,13
157delATCT stop+13 13,23 745insG stop +31 3
165insAG stop +2 5 745delG stop +23 13
175C→T R59W 1,2 759delAG stop +26 14
199insT stop+10 13 769delG+770T→A stop +16 21
218T→C L73P 13 803G→A W268X 13
Intron 3: Intron 7:
IVS3-1g→c del exon 4 13 IVS7+1del 18bp del exon 7** 12
Exon 4: IVS7+2t→c del exon 7 13
251T→G V84G 13 IVS7-9t→g 8bp into cDNA 13
254T→C L85P 13 Exon 8:
317A→C H106P 15 841delCAC H281del 13
Intron 4: 845T→A V282D 13
IVS4+1g→a splicing defect 18 856delA stop +20 13
Exon 5: 868G→C V290L 13
363insC stop +21 13 868G→A V290M 21
363insG stop +21 22 Exon 9:
376delCT stop +16 13 884T→C L295P 13
397G→T E133X 6 915delTG stop +42 18
413G→C R138P** 22 Intron 9:
428A→T D143V 13 IVS9-1g→c del exon 10 13
454C→T R152C 10,13 Exon 10:
460del 23bp stop +15 13 1004T→G V335G 13
461T→C L154P 13 1043insT stop +1 16
Exon 6: 1043A→G Y348C** 22
472G→A V158M 13 1046A→C D349A*** 12
503G→A R168H 7,13 1048T→C S350P 13
502C→T R168C 2 1053insT stop +3 13
505G→A G169E** 9,12 1072G→A G358R** 9,12
515C→T A172V 13 1081insG stop +19 13
528insT stop +1 13 1082insC stop +18 13
532C→G L178V 15 1083delT stop +3 4,13,18
538delAT stop +10 11,13 1083insG stop +18 13
542del 15bp stop +291 13 1090delAG stop +15 13
565delC stop +44 13 1091insA stop +16 18
565C→T Q189X 13,18 Intron 10:
571G→T E191X 18 IVS10+1g→a splicing defect 19
593T→G L198X 13 IVS10-1g→t del exon 11 13
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Table 4 continued. Reported mutations in the PPOX gene
Mutation Outcome Reference Mutation Outcome Reference
Exon 11: IVS12+1g→c splicing defect 18
1119G→A W373X 13 IVS12-2a→g del exon 13 13,18
1123C→T Q375X 21 Exon 13:
1147delGT stop +50 13,18 1292delAG stop +2 13
Intron 11: 1297G→C A433P*** 12
IVS11-1g→a splicing 
defect
20 1299delT stop +4 14
IVS11-11t→g mRNA 
<10%**
12 1303C→T Q435X 13,18
Exon 12: 1330delT stop 17
1239delTACAC stop +19 17 1331T→C L444P 13
1274delGT stop +7 13 1340G→A G448R 14
1281G→A W427X 13 1348T→C S450P 8
1287delA stop 13 1357G→A G453R 13
Intron 12: 1358G→T G453V 13
IVS12+1delG del exon 12 13 1384delAG stop +13 13
1. Meissner et al. (1996); 2. Warnich et al. (1996); 3. Deybach et al. (1996); 4. Frank and 
Christiano (1997); 5. Lam et al. (1997); 6. Frank et al. (1998b); 7. Frank et al. (1998a); 8. 
Frank et al. (1998c); 9. Frank et al. (1998d); 10. Frank et al. (1998e); 11. Corrigall et al. 
(1998); 12. Roberts et al. (1998); 13. Whatley et al. (1999); 14. Maeda et al. (2000); 15. 
De Siervi et al. (2000a); 16. De Siervi et al. (2000b); 17. Frank et al. (2001a); 18. Frank et 
al. (2001b); 19. Lam et al. (2001); 20. Palmer et al. (2001); 21. Corrigall et al. (2001); 22. 
Corrigall et al. (2000); 23. Donnelly et al. (2002).
*mutations in bold have been expressed in E. coli
**homozygous VP, patient heteroallelic for the mutation
***homozygous VP, patient homoallelic for the mutation
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AIMS OF THE STUDY
At the beginning of this study in 1998, two different mutations causing VP had been 
identiﬁ ed in 13 of the 22 biochemically and clinically well-characterized Finnish 
families (Mustajoki 1980; Timonen et al. 1990b). The pathogenetic mechanisms of 
VP at the molecular level were poorly known, as were the effects of mutations on 
PPOX activity.
The aims of this study were:
1. To identify the gene defects causing VP in Finland.
2. To characterize the outcome of the mutations at mRNA and polypeptide levels 
and to study the mitochondrial transport and localization of mutant and wild-type 
PPOX.
3. To investigate the clinical and biochemical outcome of patients and the genotype-
phenotype correlation among Finnish VP patients.
4. To develop methods for DNA diagnostics of VP in Finnish families.
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1. Patients and biochemical analyses
Since 1966, we have conducted a systematic follow-up of all Finnish patients known 
to have VP. To date, 143 VP patients belonging to 22 different families have been 
diagnosed, and in 20 of these families, ancestors were traced back to the 18th or 19th 
centuries using church registers (Mustajoki 1980) (Figure 10). Diagnosis of VP was 
based on mutation analysis (n=60), typical clinical symptoms with elevated faecal 
protoporphyrin excretion (n=68) (Li et al. 1986), characteristic plasma ﬂ uorescence 
emission spectrum (n=14) (Poh-Fitzpatrick 1980), low lymphocyte PPOX activity 
(n=25) (Deybach et al. 1981) and/or pedigree analysis (n=6). 
PBG and ALA were measured using the ALA/PBG Column test (Bio-Rad, CA, 
USA) as described by Mauzerall and Granick (1956). Until 1988, urinary excretions 
of uro- and coproporphyrin and faecal excretions of copro- and protoporphyrin 
were measured according to Rimington (1958) and Holti et al (1958). Since 1988, 
all measurements have been obtained using high-pressure liquid chromatography 
(HPLC) (Lim and Peters 1984; Li et al. 1986). Biochemical measurements were taken 
in adolescence or adulthood (14 to 83 y). Porphyrins and porphyrin precursors were 
measured during remission of acute symptoms but in the presence or absence of skin 
disease. Informed consent was obtained for all DNA testing and the study protocol 
was approved by the Ethics Committee of the Department of Medicine, University 
Central Hospital of Helsinki.
2. Mutation analyses 
For mutation analyses, a blood sample was available from at least one patient from 
each family. DNA was isolated from blood leucocytes using a QIAmp Blood Kit 
(Qiagen, Hilden, Germany) (Higuchi 1989) and ampliﬁ ed using polymerase chain 
reaction (PCR) (Mullis and Faloona 1987). PCR products were puriﬁ ed using the 
QIAquick PCR Puriﬁ cation Kit (Qiagen, Hilden, Germany) and sequenced using the 
dideoxynucleotide chain termination method (Sanger et al. 1977) with the Amplicycle 
Sequencing Kit (Perkin Elmer, Wellesley, MA, USA) according to the manufacturer’s 
instructions. When the mutation was identiﬁ ed in a family, DNA samples of known 
family members were either analysed using restriction digestion, when a speciﬁ c 
enzyme was available, or by direct sequencing. The analyses were repeated at least 
twice for each sample in the presence of negative and positive controls. The PCR 
conditions and primer sequences are given in Studies I-III. In addition, the DNA of 40 
or more healthy unrelated controls were tested to exclude common polymorphisms.
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To verify the outcome of the mutations at mRNA level, total RNA was extracted 
from Epstein-Barr virus transfected lymphoblastoid cell lines of patients using the 
guanidium isothiocyanate method (Chirgwin et al. 1979; Sambrook et al. 1989). 
Complementary DNA was synthesized from 5-10 µg of total RNA using Superscript 
II Rnase H- Reverse Transcriptase (Gibco BRL Life Technologies, Gaithersburg, 
MD, USA) and random hexamers or oligo(dT)s and directly sequenced as described 
above.
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Figure 10. VP pedigrees. Closed circle and square = affected female and male with clinically 
symptomatic disease; open circle and square = unaffected family member; half-ﬁ lled circle 
= asymptomatic individual carrying the affected gene; M+ = mutation-positive; M- = 
mutation-negative.
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3. Prokaryotic and eukaryotic expression of  PPOX mutations
The normal and mutant PPOX alleles were expressed in Escherichia coli using the 
pUC18 vector (Pharmacia LKB Biotechnology Inc., Picataway, NJ, USA). The 
mutations were inserted into human PPOX-pUC18 (kindly provided by Prof. S. 
Taketani, Kansai Medical University, Osaka, Japan) using Chameleon double-strand 
site-directed mutagenesis kit (Stratagene Cloning Systems, La Jolla, CA, USA) or 
by ligating mutated RT-PCR fragments as a cassette into the corresponding sites 
of the PPOX-pUC18 using T4 DNA ligase (New England Biolabs, Beverly, MA, 
USA). The details of plasmid construction are given in Studies II-III. For eucaryotic 
expression, normal and mutant PPOX fragments were ligated to the corresponding 
sites of the modiﬁ ed pCMV1-vector, pCMV5 (Andersson et al. 1989). COS-1 cells 
were transfected using 100 µM chloroquine and CaCl
2
 precipitation (Sambrook et al. 
1989). The transformed COS-1 cells were incubated in Dulbecco’s modiﬁ ed Eagle’s 
medium (Gibco-BRL, NY, USA) supplemented with 10% foetal heat-inactivated 
bovine serum and antibiotics for 48 h before harvesting.
4. Assay of  PPOX activity 
Crude cell extracts of plasmid-containing cultures were assayed and the enzyme 
activities obtained were compared with those of background activity of PPOX in E. 
coli or COS-1 cells. Transformed cells were lysed with 300 µl of incubation buffer 
(150 mM Tris-HCl, 1mM EDTA, 1% (vol/vol) Tween 20) and sonicated (3 times 
12 s), spun down for 10 min at 40C, and 50 µl of the supernatant was used for the 
PPOX activity assay (Deybach et al. 1981). Protoporphyrinogen was prepared from 
protoporphyrin IX (Porphyrin Products, Logan, UT, USA) by sodium amalgam 
reduction just before use.  The protoporphyrinogen solution was diluted with 50 mM 
GSH incubation buffer 1:1 (vol/vol) to avoid auto-oxidation, and 10 µl was used as 
a substrate in the reaction.  The assays were carried out at 370C in the dark.  At 5 and 
25 min, the samples were withdrawn and the reaction was stopped by mixing with 1 
ml of 100 mM Tris-HCl, 1 mM EDTA, 0.1% Triton-X-100 (vol/vol), pH 8.7, and 2 
mM GSH.  Background ﬂ uorescence was controlled in each series by measuring the 
buffers only. The formation of protoporphyrin was determined by ﬂ uorescence using 
a Hitachi spectroﬂ uorometer (wavelength of excitation 403 nm, emission 631 nm), 
and the protein concentration  by the method of Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Richmond, CA, USA).
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5. GFP ß uorescence, mitochondrial staining and confocal 
laser scanning microscopy 
For GFP ﬂ uorescence, the COS-1 cells were seeded on a 3-cm 6-well plate at 400 
000 cells/well and grown overnight. The 50-70% conﬂ uent cells were transfected 
with 1.5 µg of human PPOX-pcDNA3.1/CT-GFP wild-type or mutant constructs by 
lipofection using FuGENE6 transfection reagent (Boehringer Mannheim, Germany). 
The details of the plasmid construction are given in Study V. For mitochondrial 
staining, 40 nM of MitoTracker Red CMXRos (Molecular Probes, Eugene, OR, USA) 
was added to the media for 45 min at 48 h post-transfection. Cells were immediately 
ﬁ xed with 3% paraformaldehyde for 30 min at room temperature. After ﬁ xation, 
the cells were washed three times in PBS and mounted in Mowiol 4-88 mounting 
medium (Calbiochem, Germany). The cells were observed on a Leica TCS confocal 
laser scanning microscope (Leica Microsystems GmBH, Heidelberg, Germany). 
Fluorescence of GFP was excited using a 488-mm argon/krypton laser, and emitted 
ﬂ uorescence was detected with a 500- to 530-nm band pass ﬁ lter. For Mitotracker 
Red, a 543-nm helium-neon laser was used for excitation, and ﬂ uorescence was 
detected with a 565- to 699-nm band pass ﬁ lter. For 3D imaging, a stack of 30 images 
with 0.20 µm distances was taken, and the 3D picture was constructed using Leica 
Confocal Software 2.00.
6. Statistical analyses 
Fischer’s exact test was used for comparison of categorical variables (number of 
symptomatic vs. non-symptomatic patients with different mutations). Continuous 
variables (biochemical excretions in patients with different mutations or different 
symptoms) were analysed using the Mann-Whitney U-test when two groups were 
compared or Kruskal-Wallis one-way ANOVA when more than two groups were 
compared simultaneously. Logistic regression with maximum likelihood estimation 
as an optimization criterion was employed to evaluate the association between the 
occurrence of skin symptoms and biochemical excretions. The model was adjusted 
for gender, age at time of diagnosis, year of diagnosis and mutation type. Statistical 
calculations were performed with SPSS version 10.04 and NCSS 2000.
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7. Molecular modelling and polypeptide structure prediction 
The model of the 18-residue peptide PPOX-(6-23) bound to the mitochondrial import 
receptor (Tom20) was built using a Bodil modelling environment (http://www.abo.ﬁ /
fak/mnf/bkf/research/johnson/bodil.html) and Sybyl 6.8 (Tripos Inc., St. Louis, MO, 
USA). The co-ordinates of the NMR structure of rat Tom20 in a complex with the 
recognition peptide of rat aldehyde dehydrogenase (pdb-entry: 1OM2) were used 
as a template for model building.  Tertiary structure of the PPOX amino-terminus 
was predicted using program Swiss-Model (Peitsch 1996) (http://www.expasy.org/
swissmod/SWISS-MODEL.html) with MAO-B structure (pdb-entry: 1GOS) as a 
template. Secondary structure calculation and ﬁ gure drawing were carried out using 
PredictProt (Rost and Sander 1993; Rost and Sander 1994; Rost 1996) and MolMol 
(Koradi et al. 1996). The details of the model building are given in Study V. 
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1. Mutations in the PPOX gene among Finnish VP patients 
(II,III,V)
1.1. IdentiÞ cation and characterization of  the mutations
To identify the mutations in the PPOX gene, all exons and exon-intron boundary 
regions were directly sequenced after ampliﬁ cation of genomic DNA samples of 
22 Finnish VP patients representing their families. In each case, the mutation was 
conﬁ rmed by repeating ampliﬁ cation and sequencing in both sense and antisense 
orientation, and by restriction digestion whenever available (Figure 11). 
1169 bp
616 bp
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C G A T C G A TC G A T
Figure 11. Identiﬁ cation of a mutation using two alternative methods. A Restriction site 
analysis of a patient’s genomic DNA in the presence of negative and positive controls. A 
1260-bp fragment spanning exons 2 to 5 was PCR-ampliﬁ ed and digested with Bsu36I. 
Since the mutation 338G→C abolishes a restriction site, an extra band of 1169 bp is visible 
in agarose gel electophoresis for a heterozygous patient. Lane 1 DNA molecular weight 
marker VI (Boehringer Mannheim, Germany); Lane 2 the patient’s DNA sample; Lane 3 
mutation-positive control; Lanes 4 and 5 mutation-negative controls; Lane 6 undigested 
sample. B Direct sequencing of the genomic DNA of a patient (left) in the presence of 
mutation-positive (middle) and mutation-negative (right) controls. The mutation G→C is 
seen as an extra band in PAGE electrophoresis for a heterozygous patient.
42
Mikael von und zu Fraunberg
DNA samples of healthy unrelated Finnish controls (n≥40) were analysed to exclude 
common polymorphisms. Eight different mutations were identiﬁ ed in the PPOX gene 
among the 22 known Finnish VP families, and the ancestors were traced back to the 
18th or 19th centuries using church registers (Figure 12).
The outcomes of the mutations were studied by ampliﬁ cation and sequencing 
of the reverse-transcribed total RNA obtained from patients’ EBV-transformed 
lymphoblast cell lines. Seven of the mutations (I12T, 78insC, IVS2-2a→c, 338G→C, 
R152C, 470A→C and L401F) were identiﬁ ed in the direct sequencing of cDNA. This 
method gives in most cases a rough estimation of the steady-state transcript level of 
the mutant allele since the mutant allele is detected in cDNA if the level exceeds 30% 
I12T
78insC
R152C
609delG
L401F
Mutation unknown
IVS2-2a c
338G C
470A C
Figure 12. Geographical origin of the 22 VP families in Finland.
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of the normal allele. In addition, for three mutations, IVS2-2 a→c, 338G→C and 
470A→C, the relative amount of expressed mutant allele was estimated by comparing 
bands corresponding to the mutant and wild-type alleles in the agarose gel (Table 5).
To further characterize the PPOX mutations and to conﬁ rm the enzymatic defect, 
the normal and ﬁ ve mutant polypeptides were expressed both in prokaryotic and 
eukaryotic cell lines. PPOX activities of the normal transcripts and mutants were 
measured in E. coli and in COS-1 cells (Table 5, Figure 13). The normal allele 
showed high levels of PPOX activity in both expression systems; the increase was 
8-fold in E. coli and 3-fold in COS-1 cells compared with background activity. This 
validated the use of both expression systems (Table 5). 
Transport of the wild-type and seven mutated PPOX polypeptides to mitochondria 
was investigated by constructing the corresponding green ﬂ uorescent protein (GFP) 
fusion proteins, expressing them in COS-1 cells and studying their intracellular 
localization (Table 5).
Table 5.  Characterization of mutations in Finnish VP patients.
Mutation Outcome Residual activity cDNAa mRNA Mito- Patients/ Ref
E. coli COS-1 levelb chondrialc families
35T→C  Ex 2 I12T 3% 1% + n.d. + 12 / 2 II
78insC Ex 2 stop +8 amino 
acids
0 0 + n.d. + 5 / 1 III
IVS2-2a→c IVS 2 34 bp retention 
of intron 2
0 0 + N + 2 / 1 III
338G→C Ex 4 Deletion exon 4 5% 0 + ↓ + 11 / 2 III
454C→T Ex 5 R152C 5% 5% + n.d. + 67/ 11 IIId
470A→C Ex 5 Deletion exon 5 
+ 19 bp retention 
of intron 5
1% 0 + N + 1/ 1 III
609delG Ex 6 Frameshift or 
splicing defect
n.d. n.d. n.d. n.d. n.d. 3/ 2 -e
1203A→C Ex 11 L401F n.d. n.d. + n.d. + 2/ 1 III
a + mutation seen in direct sequencing of cDNA
btranscript level of the mutant allele compared to normal allele, ↓ reduced, N normal
clocalization of the corresponding GFP-fusion protein, + localized in mitochondria
dmutation reported in Acta Haematologica (1997) 98 (suppl 1) 1-128 (Abstr.) and in Frank 
et al. (1998e) and Whatley et al. (1999).
eunpublished data
n.d. not done
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Figure 13. Enzyme activities of normal and mutant PPOX alleles measured in E. coli and 
COS-1 cells.
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1.2. Outcomes of  the mutations
I12T (35T→C) Substitution of the non-polar isoleucine with the polar threonine in 
exon 2 (Figure 14) resulted in the loss of enzymatic activity in both prokaryotic and 
eukaryotic expression systems (Table 5). The mutation could be detected with BanI 
digestion since it abolished a restriction site. The full-length PPOX with the I12T 
mutation is transported into mitochondria, although the mutation is able to disrupt the 
N-terminal targeting signal in a truncated polypeptide with only the ﬁ rst 29 amino 
acids. In the two families studied, the mutation 35T→C co-segregated with a single 
nucleotide polymorphism 767C→G in all patients. The C to G transversion in exon 
7 at position 767 converted proline to arginine (P256R) but demonstrated up to 50% 
residual activity in E. coli and normal activity in COS-1 cells. P256R polymorphism 
has also been reported in other western European populations (Whatley et al. 1999). 
This study demonstrated that this amino acid substitution did not affect the PPOX 
activity. Neither of these two amino acid changes was detected in any of the 40 
unrelated healthy Finnish controls.
78insC Insertion of nucleotide C after nucleotide position 78 in exon 2 caused a 
frameshift and a premature stop codon 8 codons downstream in exon 2. As expected, 
the mutation abolished enzyme activity in both E. coli and COS-1 cells, but the GFP 
fusion protein studies showed that it nonetheless targeted into mitochondria (Table 
5).
IVS2-2a→c  –2a→c substitution at the 3’ acceptor splice site of intron 2 altered the 
consensus sequence (ag/GT→cg/GT) and activated a cryptic splice (cag/gc) 35 bp 
upstream from the authentic splice site. Exons 1 and 2 were transcribed normally, 
but a frameshift and a premature stop codon occurred in exon 3. The predicted length 
of the translated polypeptide was 47 amino acids. The mutation abolished enzyme 
acticity in both E. coli and COS-1 cells, but mitochondrial transport was unaffected 
(Table 5). The mutation was conﬁ rmed by restriction cleavage since it abolished a 
BstNI cleaving site.
338G→C (–1G→C) Mutation at the 5’ splice site of intron 4 altered the consensus 
sequence (AG/gt→AC/gt) and resulted in exon 4 skipping. Exons 1 to 3 were 
transcribed normally, but a frameshift and a premature stop codon occured in exon 5. 
In RT-PCR, the steady-state level of the mutant transcript in the patient’s lymphocytes 
was markedly decreased compared with that of the normal allele. The mutation 
abolished enzyme acticity in both E. coli and COS-1 cells, but the mitochondrial 
transport was unaffected (Table 5). The predicted length of the translated polypeptide 
was 103 amino acids. The mutation was conﬁ rmed by restriction cleavage since it 
abolished a Bsu36I cleaving site.
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609delG*
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 E13
5' 3'
5 6 7 8 9 11 12 131045' 2 3'3178insC
H N2 COOH
PPOX cDNA 5 6 7 8 9 11 12 131045' 2 3'31
H N2 COOH
35 bp
5' 2 4 5 6 7 8 93 11 12 1310 3'1IVS2-2 a c
H N2 COOH
5' 2 53 6 7 8 9 11 12 13 3'101338G CExon 4-1 G C
H N2 COOH
470A C
Exon 5-2 A C
19 bp
4 6 7 8 9 11 12 13 3'105' 2 31
H N2 COOH
5 6 7 8 9 11 12 131045' 2 3'31
H N2 COOH
454C T
R152C 5 6 7 8 9 11 12 131042 3'315'
5' 5 6 7 8 9 11 12 131042 3'3135T C+ 767C GI12T + P256R
H N2 COOH
1203A C
L401F 5 6 7 8 9 11 12 131045' 2 3'31
H N2 COOH
H N2 COOH
Figure 14. Schematic representation of outcomes of the mutations. Above exon/intron 
structure of human PPOX gene; solid and open boxes represent protein-coding and 
untranslated regions. Below the cDNA and protein translation are shown for each mutation; 
solid bars represent normally translated amino acids and open bars represent nonsense amino 
acids. * unpublished data; not conﬁ rmed at cDNA level.
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R152C (454C→T) Substitution of basic arginine residue with neutral, sulphur-
containing amino acid cysteine (R152C) resulted in a dramatic decrease of enzyme 
activity (5% of wild type activity) in both E. coli and COS-1 cells (Table 5). 
This arginine residue has been conserved in humans, mice, bacteria, yeast and 
plants, indicating its importance in PPOX function. The mutation had no effect on 
mitochondrial transport and was not detected in any of the 80 alleles of unrelated 
healthy controls, excluding a common polymorphism. The mutation could be detected 
with HhaI digestion since it abolished a restriction site.
470A→C (–2A→C) Mutation at the 5’ splice site of intron 5 altered the consensus 
sequence (AG/gt→CG/gt) and resulted in exon 5 skipping and activation of a 
cryptic splice site (ag/tc) 19 bp upstream from the authentic 3’ splice site of intron 
5. The reading frame was unaffected and exons 1 to 4 and 6 to 13 were transcribed 
normally. The mutation abolished enzyme acticity in both E. coli and COS-1 cells, 
but mitochondrial transport was not affected (Table 5). The predicted polypeptide 
contained 112 translated amino acids encoded by exons 1 to 4, followed by 7 amino 
acids encoded by the inserted fragment of intron 5 instead of exon 5, and 320 normally 
translated amino acids encoded by exons 6 to 13. The mutation was conﬁ rmed by 
restriction cleavage since it abolished a Bsu36I cleaving site.
L401F (1203A→C) Mutation in exon 11 was predicted to result in a substitution of 
a non-polar amino acid phenylalanine for non-polar leucine (L401F). The effect of 
this apparently mild amino acid change on the function of the enzyme was difﬁ cult to 
predict since the three-dimensional structure of the PPOX has yet to be determined. 
Homology comparisons showed that this leucine residue was conserved in humans, 
mice and yeast but not in bacteria. The mutation had no effect on mitochondrial 
transport. The mutation segregated within the family and was not detected in any 
of the 80 alleles of unrelated healthy controls, excluding a common polymorphism. 
No other mutations were detected by direct sequencing of the exons and intron-exon 
boundaries of the proband’s PPOX gene.
609delG Deletion of nucleotide G after nucleotide position 609 in exon 6 was 
detected in the direct sequencing of a patient’s genomic DNA (unpublished data). 
The mutation resided at the 5’ splice site of intron 6 and was predicted to cause either 
a frameshift with a premature stop codon at exon 8 or a splicing defect. This could 
not be conﬁ rmed at the mRNA level since cDNA analysis of the mutation is yet to be 
accomplished. The mutation segregated within the family and was not detected in any 
of the 80 alleles of unrelated healthy controls, excluding a common polymorphism. 
No other mutations were detected by direct sequencing of the exons and intron-exon 
boundaries of the proband’s PPOX gene.
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2. Mitochondrial targeting of  PPOX (V)
Transport of the wild-type and seven PPOX mutants (I12T, 78insC, 
IVS2-2a→c, 338G→C, R152C, 470A→C and L401F) to mitochondria was 
investigated by constructing green ﬂ uorescent protein (GFP) fusion proteins in which 
GFP was located in the carboxyl-terminal end of PPOX. COS-1 cells were transfected 
with the constructs and GFP ﬂ uorescence was analysed with confocal laser scanning 
microscopy.  The cells expressing the wild-type PPOX-GFP demonstrated a typical 
mitochondrial pattern (Figure 15A) that was clearly distinguishable from the cytosolic 
pattern of GFP-constructs alone (Figure 15B). Each of the seven PPOX mutants 
showed a pattern similar to the PPOX-GFP, indicating that transport to mitochondria 
in all of them was unimpaired.
We showed that the 28 amino-terminal amino acids of PPOX contained an 
independently functioning mitochondrial targeting signal. In addition, experiments 
with a GFP-fusion protein where amino acids 5 to 24 were removed revealed that 
Figure 15. 3D image of a COS-1 cell transfected with the PPOX-GFP construct or GFP alone. 
After transfection, the cells were ﬁ xed and analysed by ﬂ uorescence confocal microscopy. A 
PPOX-GFP; B GFP alone.
Figure 16. Alignment and secondary structure prediction of PPOX peptide sequences using 
PredictProtein (Rost 1996). Residues are numbered according to the human sequence. 
Invariant residues are coloured in yellow and internal leucine-rich α-helical segments in 
blue (next page)
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-------91--------101-------111-------121-------131-------141-------151-------161-------171-------181-
vlpvrgdhpaaqnrflyvggalhalptglrgllrpsppfskplfwaglreltkprgkepdetvhsfaqrrlgpevaslamdslcrgvfagnsrelsirscf
vlpvrgdhpaaqnrflyvggtlhplpsglrgllrpsppfskplfwaglrellkprgkepdetvhsfaqrrlgpevaslamdslcrgvfagnsrelsirscf
llrissnspsaknryiyypdrlneipssilgsiksqpalrpmplammlepfrkskrdstdesvgsfmrrrfgknvtdrvmsamingiyagdlndlsmhsmf
--riraadpaakrryvytrgrlrsvpasppaflasdilplgarlrvagelfsrrapegvdeslaafgrrhlghratqvlldavqtgiyagdveqlsvaatf
lvlgdptap----rfvlwngklrpvpskltdlpffdlmsiggkiragfgalirpsppgreesveefvrrnlgdevferliepfcsgvyagdpsklsmkaaf
viapgg----grrvsllsrgklrpmpagmgmvlptwpfvtttvlsagldlviprrlpdhdvaigaflrqrlgdgivrrfadpmvggiygagidelsldavl
lvlgdpnap----rfvlwkgklrpvpskltdlaffdlmsipgklragfgailrpsppgheesveqfvrrnlggevferliepfcsgvyagdpsklsmkaaf
lvnn-----atgqsyvlvnrtlhpmpkgvmgiptkiapfvstglfaamdfilpasktkddqslgeffrrrvgdevvenliepllsgiyagdidklslmstf
iqsidkgciadkkflldpsdklvqvpnsisttvkflnplgkglitgmmgewfrkkspgqdesvesicdrrfgnnyisnmisallrgiygddvsllsakrtf
1---------11--------21--------31--------41--------51--------61--------71--------81-
H. sapiens : mgrtvvvlgggisglaasyhlsrapcppkvvlvesserlggwirsvrgpngaifelgprgirpagalgartlllvselgldse
M. musculus : mgrtvivlgggisglaasyhlirgpsppkvilvegskrlggwirsirgsdgaifelgprgirpagalgartlllvselglese
S. pombe : ---siaicgggiaglstafylarlipkctidlyekgprlggwlqsvkipgtvlfeqgprtlrpagvaglanldlisklgiedk
M. xanthus : -gmnvavvgggisglavahhlrsr--gtdavllessarlggavgthal-agylveqgpnsfldre---patralaaalnleg-
A. thaliana : -----vivgggisglciaqalatkhaapnlivteakdrvggniitree-ngflweegpnsfqpsd----pmltmvvdsglkdd
P. freudenr. s. : ---hlvvvgggitglaaawqgmar--garvsvvesddhfggkvvtdrr-dgflveqgpdsyrpaa------lklieelglsdq
N. tabacum : -----vivgagisglciaqvmsany--pnlmvteardraggnittver-dgylweegpnsfqpsd----pmltmavdcglkdd
B. subtilis : --khvviigggitglaaafymekeilpleltlveasprvggkiqtvkk-dgyiiergpdsflerkksap---qlvkdlglehl
S. cerevisiae : ----vavvgggvsglcftyflsklrpdveitlfesqnrtggwiyscntrnpimlekgprtlrgvsdgtvlimdtlkdlgkeav
S1 H1 S2 S3 S4 H2
------191-------201-------211-------221-------231-------241-------251-------261-------271-------281--
pslfqaeqthrsillglllgagrtpqpdsalirqalaerwsqwslrgglemlpqalethltsrgvsvlrgqpvcglslqaegrwkvslrdssleadhvisa
pslfqaeqthrsillglllgagqspqpdsslirqaraerwsqwslrgglevlpqalhnhlaskgvtvlsgqpvcglslqpegrwkvslgdssleadhiisa
gflakiekkygnitlglirallalaepktaelsnsm-kstsmfafkegietitlsiaihlnkpaktlvphktqslvdvngqayeyvvfanssrnlenlisc
pmlvkmerehrslilgairaqkaqrqaalpagtapkls-galstfdgglqvlidalaahvgarveglaredggwrliieehgr------raelsvaqvvla
gkvwkleqnggsiiggtfkaiqerknapkaerdprlpqgqtvgsfrkglrmlpeaisarlgsk---vklswklsgitklesggynltyelvsvqsksvvmt
pslrdnerdhrslmvaslaggrstgqnnsagtrgpaas--pfrtlrgglgqlidalvdqlraggvellv-----ntsvdllgrdgvhlsdgrvpadavvla
gkvwkleetggsiiggtfkaikersstpkaprdprlpkgqtvgsfrkglrmlpdaisarlgswklssitksekggyhltyetpegvvslqsrsivmtvpsy
pqfyqteqkhrslilgmkkt-----rpqgsgqqltakkqgqfqtlstglqtlveeiekqlkltk--vykgtkvtklshsgscysleldngvtldadsvivt
kkiyynelkhgsntqamidnmgksrskktenlhqsllkkypmlglaggletfpkivrnalneknvkivtgnpvtqimkrpanettiglkaksgdfdhlrlt
-----291-------301-------311-------321-------331-------341-------351-------361-------371-------381---
ipasvlsellpaeaaplaralsaitavsvavvnlqyqgahlpvqgfghlvpssedpgvlgivydsvafpeqdgsppglrvtvmlggswlqtleasgcvlsq
ipaselskllpaeaaplarilstikavsvavvnlqyrgaclpvqgfghlvpssedptvlgivydsvafpeqdgnppslrvtvmlggywlqklkaaghqlsp
pkmetpts-------------------svyvvnvyykdpnlpirgfgllipsctpnnvlgivfds----eqnnpengskvtvmmggsay-tkntsliptnp
apahatakllrplddalaalvagiayapiavvhlgfdagtlpadgfgflvpaeeqrrmlgaihasttfpfraeg-grvlyscmvggarqpglveqd----e
vpshvasgllrplsesaanalsklyyppvaavsisypkeagelkgfgqlhprtqgvetlgtiyssslfpnrappgrilllnyiggstntgilsks------
ggvassarllrpqlpaaaralaqiplasttivslawpvsafdvapdsqgwleadagpvsgltassikfagrapd-gsvlmrvfvpdkrgpltdap-----d
vasnilrplsvaaad----alsnfyyppvgavtitypqeagelkgfgqlhprtqgvetlgtiyssslfpnrapkgrvlllnyiggaknpeilsktesvvdr
aphkaaagml--selpaishlknmhstsvanvalgfpegsmehegtgfvisrnsdfaitactwtnkkwphaape-----gktllrayvgkagdesivdlsd
itppkiakllpkdqnslsklldeiqsntiilvnyylpnkdadlqgfgylvpksnknpllgvifdsvistnpnalnkytkvtamiggcmlnehgvpv-vpsr
----391-------401-------411-------421-------431-------441-------451-------461-------471----
elfqqraqeaaatqlglkempshclvhlhkncipqytlghwqklesarqfltahrlpltlagasyegvavndciesgrqaavsvlgtepns
elfqqqaqeaaatqlglkeppshclvhlhkncipqytighwqkldsamqfltaqrlpltlagasyegvavndciesgrqaavavlgtesns
eeavnnalkalqhtlkisskptltnatlqqncipqyrvghqdnlnslkswieknggrilltgswyngvsigdcimnghstarklaslmnss
dalaalareelkalagvtarpsftrvfrwplgipqynlghlervaaidaalq-rlpglhlignaykgvglndcirnaaqladalvagnts-
egelveavdrdlrkmlikpdplklgvrvwpqaipqflvghfdildtakssltssgyglflggnyvagvalgrcvegayetaiev-------
dellsavidhvrpllgvhgepgltqitrwhkvmpkytvghleraavvdstlaeqrptwavagsalhgvglpdcisdarhsadevidaalaa
dlrkmlikpkaqdplvvg-------vrvwpqaipqflvghldtlstakaamndnglglflggnyvsgvalgrcvegayevasevtg-----
ndiinivledlkkvmningepemtcvtrwhesmpqyhvghkqrikelrealasaypgvymtgasfegvgipdcidqgkaavsdal------
evtinavkdalnnhlgisneagqweftiadrclprfhvgydawqerarklqesygqtvsvggmgfsrspvpdvivdgfndalql-------
S12S11 S13 S14H9 H10
H8 S7 S8 S9 S10H7
H11 S15 S17H12 H13S16
H3 H4 H5 H6S5 S6
Figure 16 (see previous page)
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amino acids 25 to 477 of PPOX contained at least one additional mitochondrial 
targeting signal. Secondary structure prediction of PPOX revealed several internal 
leucine-rich a-helical segments with a net positive charge, which could act as internal 
mitochondrial targeting signals (Figure 16).
To create a structural hypothesis for the molecular recognition of the amino-
terminal mitochondrial targeting signal of PPOX, we constructed an α-helical 
model of PPOX-(6-23) and a model of the interaction between PPOX-(6-23) and 
the mitochondrial import receptor Tom20. The model placed the LXXXIXXL (Leu8, 
Ile12 and Leu15) motif of PPOX-(6-23) in contact with the hydrophobic groove on 
the Tom20 surface (Figure 17). 
We tested our structural model by mutating the PPOX-(6-23) residues Ile12 into 
threonine and residues Leu8 and Leu15 into glutamine. These amino acid substitutions 
disrupted the hydrophobic face of the LXXXIXXL helix model, which should affect 
the capability of interaction with Tom20. All three mutations caused a disruption 
of PPOX transport into mitochondria, conﬁ rming that each of these residues was 
essential for PPOX targeting. In the amino-terminus of PPOX, the LXXXIXXL motif, 
including residues Leu8, Ile12 and Leu15, appeared to be crucial for the putative 
interaction between PPOX and Tom20.  
Figure 17. Model of 
the interaction between 
Tom20 (grey) and 
PPOX-(6-23) (blue). Rat 
aldehyde dehydrogenase 
presequence peptide 
pALDH-(12-22) in a 
complex with Tom20 
(NMR structure, pdb-
entry: 1OM2) is shown in 
orange. The hydrophobic 
Leu8, Ile12 and Leu15 
residues are organized on 
one side of the helix in the 
model. The model locates 
the motif LXXXIXXL of 
PPOX-(6-23) in contact 
with the hydrophobic 
groove on the surface of 
Tom20. © The American 
Society for Biochemistry 
& Molecular Biology, 
reprinted with permission.
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3. Homozygous variegate porphyria  molecular genetics and 
long-term follow-up (II)
The molecular defect was characterized from a homozygous VP patient, who was 
followed up in 1980-2000. The patient was homoallelic with amino acid substitutions 
I12T and P256R. He developed a severe skin disease post-partum with fragility, blister 
formation and scarring. The patient had never experienced acute attacks, although 
he had been exposed to potential predisposing agents such as infections. Minor 
verbal and visuospatial deﬁ ciencies as well as ﬁ ne motor co-ordination disturbances 
were present, but mental status had remained normal. Increased serum creatinine 
levels, hematuria, proteinuria and increased blood pressure indicated renal failure. 
Heterozygous relatives with the I12T mutation experienced no cutaneous symptoms 
or acute attacks (Figure 10, pedigree IX). In another family with the mutation I12T 
(Figure 10, pedigree VIII), only one patient had experienced two acute attacks in her 
youth due to use of sulphonamides, suggesting a milder phenotype of this mutation 
in the heterozygous state. 
4. Genotype-phenotype correlation in VP (IV)
The correlation between PPOX genotype and phenotype was investigated for 90 
patients with the three most common Finnish mutations R152C, I12T and 338G  C. 
Twenty-two (24%) had experienced acute attacks, 36 (40%) photosensitivity and 12 
(13%) both symptoms before or during the follow-up period from 1966 to 2001 (Table 
6). None of the patients with the I12T mutation manifested photosensitivity, and only 
one out of 12 patients had experienced two acute attacks in her youth. The occurrence 
of photosensitivity was signiﬁ cantly lower in the I12T group compared with the 
R152C group (p=0.001), whereas no signiﬁ cant differences between the R152C and 
338G  C groups could be observed.
Table 6. Clinical manifestations and biochemical characteristics (mean±S.E.) in VP patients 
with the three most common Finnish mutations.
Mutation Photo-
sensitivity 
and acute 
attacks
(%)
Photo- 
sensitivity 
only
(%)
Acute 
attacks 
only
(%)
Symptom-
free
(%)
Urinary 
copro-
porphyrin
(nmol/d)
Urinary
uro- 
porphyrin
(nmol/d)
Faecal 
copro-
porphyrin
(nmol/g)
Faecal
proto-
porphyrin
(nmol/g)
I12T 0 0 8 92 164±12 30±11 67±38 156±67
R152C 15 34 10 40 743±124 105±15 212±28 554±50
338G→C 18 9 18 55 981±499 158±65 113±34 361±82
52
Mikael von und zu Fraunberg
Patients with the I12T mutation excreted signiﬁ cantly less uro- and coproporphyrins 
in urine than those with the R152C (p=0.001 for coproporphyrin and p=0.01 for 
uroporphyrin) or 338G→C (p=0.01 for coproporphyrin) mutation. The excretions 
of PBG and ALA in remission were also lowest in the I12T group. No differences in 
urinary excretions of uro- and coproporphyrins were observed between the R152C 
and 338G→C groups. Patients with the I12T mutation excreted signiﬁ cantly lower 
amounts of copro- and protoporphyrins in faeces than patients with the R152C 
(p=0.001 for coproporphyrin and p=0.0002 for protoporphyrin) or 338G→C (p=0.01 
for protoporphyrin) mutation.  The plasma ﬂ uorescence spectrum was normal in three 
patients tested in the I12T group, whereas in the R152C group, it was positive in eight 
out of nine patients and in the 338G→C group in two out of three patients.
5. Biochemical Þ ndings and prognosis of  VP (IV)
To evaluate the prognostic value of biochemical tests in VP, results were compared 
between patients known to have experienced acute symptoms and/or skin symptoms 
and asymptomatic patients who had never been clinically active. Regardless of 
mutation type, urinary and faecal excretions of porphyrins were signiﬁ cantly higher 
in patients with prior symptoms, even during remission. The faecal protoporphyrin 
test was 92% accurate in predicting those individuals who would remain symptom-
free with respect to acute attacks. Normal protoporphyrin excretion in the post-
menopausal phase was demonstrated in one patient, who had previously experienced 
cyclical acute attacks. The negative predictive value for skin symptoms was 92% 
if the measurement was made during post-puberty. A 64-year-old patient, who had 
experienced mild skin fragility in his youth, had normal porphyrin excretion in 
faeces and urine but a positive plasma ﬂ uorescence spectrum for VP. In contrast, 
normal urinary excretion of porphyrins, PBG or ALA, or normal faecal excretion 
of coproporphyrin did not predict freedom from symptoms for VP patients; the 
negative predictive values varied from 61% to 82%. Urinary coproporphyrin levels 
were positively correlated with the risk of both skin symptoms and acute attacks, 
and virtually all patients with an excretion of more than 1000 nmol/d experienced 
skin symptoms, acute attacks, or both. Similarly, 90% of patients with faecal 
coproporphyrin excretion exceeding 200 nmol/g (twice the upper normal limit) were 
symptomatic.
6. Sensitivity and speciÞ city of  biochemical tests in the diag-
nosis of  VP (I)
The sensitivity and speciﬁ city of biochemical screening for VP were studied among 
38 family members for whom both DNA analysis and biochemical analysis were 
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available. These individuals were either asymptomatic or had experienced occasional 
skin symptoms, acute attacks, or both.  The sensitivity of urinary and faecal 
coproporphyrin analysis was 48% and 52%, respectively. The sensitivity of urinary 
uroporphyrin analysis was 71% and of faecal protoporphyrin 77%. None of the 
biochemical measurements gave false-positive results, although urinary excretion of 
coproporphyrins may increase, for example, in many liver diseases and heavy metal 
intoxications (Moore et al. 1987). In two patients, the sensitivity of biochemical 
analysis was increased up to 83% by combining the results of faecal protoporphyrin 
and urinary coproporphyrin tests. The sensitivity of biochemical analysis could not 
be further improved by combining other tests. The plasma ﬂ uorescence emission 
spectrum, measured for 15 patients, was characteristic for VP in all symptomatic 
patients, even in remission, but failed to detect four asymptomatic patients who 
excreted normal amounts of porphyrins in urine. The overall sensitivity of plasma 
ﬂ uorescence analysis was 70%.
ROC-curve analysis was performed on 55 patients and 53 healthy relatives, 
including both individuals tested and not tested for mutation, for whom the results of 
all biochemical tests were available (unpublished data) (Figure 18). According to this 
analysis, the faecal protoporphyrin test was slightly better than the other screening 
tests in remission. Areas under curves were 0.93 [95% conﬁ dence interval (CI), 0.88-
0.98] for fecal protoporphyrin, 0.89 (95% CI, 0.82-0.96) for fecal coproporphyrin, 
0.90 (95% CI, 0.84-0.96) for urinary uroporphyrin, 0.86 (95% CI, 0.79-0.93) for 
urinary coproporphyrin, 0.78 (95% CI, 0.69-0.87) for urinary ALA and 0.74 (95% CI, 
0.64-0.83) for urinary PBG.
Figure 18. Comparison of 
sensitivity and speciﬁ city of 
different biochemical tests for 
VP in remission. (1) Faecal 
protoporphyrin; (2) Faecal 
coproporphyrin; (3) Urinary 
uroporphyrin; (4) Urinary 
coproporphyrin; (5) Urinary 
ALA; (6) Urinary PBG
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1. Mutations in the PPOX gene among Finnish VP patients
1.1. Genetic heterogeneity of  VP in Finland
This series of investigations revealed eight different mutations in the PPOX gene 
among the 22 known Finnish VP families. This demonstrates the genetic heterogeneity 
of the disease in Finland, as in other countries. Seven of the mutations are family-
speciﬁ c and have thus far only been found in Finland, whereas the major mutation 
(R152C), which was identiﬁ ed in 11 (50%) of the 22 Finnish VP families, has also 
been reported in France and in USA (Frank et al. 1998e; Whatley et al. 1999).
A founder effect was observed among VP patients in Finland, in contrast to 
AIP, porphyria cutanea tarda and erythropoietic protoporphyria. The dual theory of 
inhabitation supported by recent analyses of Y chromosome haplotypes suggests that 
the early migration wave of eastern Uralic speakers took place some 4000 years ago 
(Kittles et al. 1998; Peltonen et al. 1999). The majority of the genes of the present 
Finnish population originated from later founder populations, which migrated from 
the south over the Gulf of Finland approximately 2000 years ago. Up to the 16th 
century, only the southwest and southeast corners and the coastal areas were regularly 
inhabited, with the population expansion in the north and east starting for the most 
part after 1500 (Norio et al. 1973). 
The distribution of the major mutation R152C coincides with the early settlement 
of the Finnish population in the south-western part of the country, suggesting that the 
putative founder mutation emerged in the population more than 15 to 25 generations 
ago (Norio et al. 1973). Since the mutation has also been reported in France and in 
USA (Frank et al. 1998e; Whatley et al. 1999), it is possible that it has migrated from 
Central Europe during the late immigration  ca. 2000 years ago. However, this has not 
been conﬁ rmed by haplotype studies. Another possible explanation would be that the 
mutation has propagated during the internal migration movement, which began in the 
16th century from a small southeastern area in South Savo to the middle, western and 
ﬁ nally northern and eastern parts of the country (Figure 19). 
1.2. Effects of  the mutations on PPOX function
Eight mutations, including three amino acid substitutions, an insertion and three 
splicing defects, were identiﬁ ed among Finnish VP families. The outcome of the 
mutation 609delG was not conﬁ rmed at the mRNA level, and since it resides in 
the exon 6-intron 6-boundary region, it is predicted to cause either a frameshift or 
a splicing defect. The consequences of the mutations were studied at the mRNA 
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and polypeptide levels and mitochondrial transport and localization of mutant and 
wild-type PPOX were investigated to elucidate the pathogenetic mechanisms at a 
molecular level. 
LATE IMMIGRATION
(Southern wave,
~2000 years ago)
EARLY IMMIGRATION
(~4000 years ago)
RUSSIA
SWEDEN
NORWAY
INTERNAL IMMIGRATION
(16th century- )
Late settlement
Early settlement
South
Savo
Figure 19. Geographical origin of the Finnish VP families and the settlement of Finland. 
Closed circles the founder mutation R152C; Open circles other mutations. The grey line 
indicates the northern and eastern boundaries of the early settlement in the 16th century. 
Adapted from Nevanlinna (1972); Norio et al. (1973).
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1.2.1. Splicing defects 
Three of the eight mutations were splicing defects. Two of the mutations were located 
at the 5’ donor splice site and one at the 3’ acceptor site. The consensus sequence 
for RNA splicing is known (Figure 20), but the splicing mechanisms have not been 
thoroughly clariﬁ ed. Studies of different types of mutations at the splice sites have 
provided useful information about aberrant splicing patterns (Krawczak et al. 1992; 
Nakai and Sakamoto 1994).
Interestingly, in the case of mutation 338G→C (-1G→C), exon skipping was 
preferred, although a potential cryptic splice site (ACAG/GTTC) resembling the 
authentic splice site (TCAG/GTAA) existed 48 bp upstream of the authentic splice 
site in exon 4. This may support the “exon-deﬁ nition hypothesis” derived from 
experimental analyses stating that each exon sequence in the pre-mRNA is deﬁ ned 
and then the introns between the exons are recognized by splicing machinery (Niwa et 
al. 1992). According to the model, intron retention is permitted only when the intron 
is small enough to satisfy the exon length limitation. In this case, the total length 
of exon 4, intron 4 and exon 5 was 756 bp, which may violate the length limitation 
and thus prevent intron 4 retention. This kind of multiple aberrant splicing pattern 
with simultaneous exon skipping and cryptic splice site activation appears to be an 
infrequent phenomenon, as it was not documented in the database consisting of 209 
point mutations leading to aberrant splicing (Nakai and Sakamoto 1994).
In the case of the mutation IVS2-2a→c, the –2a→c substitution at the 3’ acceptor 
site of intron 2 causes a cryptic splice (cag/gc) activation 35 bp upstream from 
the authentic splice site. Cryptic splice site activation is a relatively common 
phenomenon, occurring in 30% of splice site mutations. The activated cryptic splice 
sites are usually located relatively near the authentic splice site within 100 nucleotides 
(Nakai and Sakamoto 1994). In the activation of 3’ cryptic splice sites, the cryptic 
sites downstream from the authentic sites are selected more frequently (Nakai and 
Sakamoto 1994). In this case, however, the cryptic site was located upstream from the 
authentic site, indicating that splice site selection is not a simple one-way scanning 
process.
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Figure 20. Consensus sequences for RNA splicing in higher eukaryotes. Adapted from 
Alberts et al. (1994).
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1.2.2. Decrease in enzymatic activity in prokaryotic and eukaryotic cells
The loss of enzymatic function of the truncated polypeptides 78insC, IVS2-2a→c 
and 338G→C was expected since they included less than 103 of the 477 amino acids 
(22%) of the normal polypeptide. The mutation 470A→C coded a polypeptide in 
which 45 amino acids encoded by exon 5 were missing. Since less than 1% enzyme 
activity was observed in both E. coli and COS-1 cells, the domain coded by exon 5 
is essential for enzyme function. In the case of mutation R152C, the substitution of 
basic arginine residue with neutral, sulphur-containing amino acid cysteine resulted 
in a dramatic decrease of enzyme activity (5% of wild-type activity) in both E. coli 
and COS-1 cells, conﬁ rming the causality of the mutation and the disease. This 
arginine residue is evolutionarily conserved in humans, mice, bacteria, yeast and 
plants, indicating its importance in PPOX function (Figure 16).
Our ﬁ ndings are in line with other studies, where enzyme activities of 0-10% have 
been reported for VP-causing mutations in prokaryotic expression systems (Meissner 
et al. 1996; Dailey and Dailey 1997a; Roberts et al. 1998; Morgan et al. 2002). In 
many cases, the effect of a single nucleotide change on the enzyme function is difﬁ cult 
to predict, and the expression of the mutated allele in vitro is the only reliable way to 
exclude a rare polymorphism. The results must be interpreted with caution, however, 
since the accurate measurement of low tissue activities is technically complicated 
and the PPOX activity in vivo may be modiﬁ ed by its mitochondrial environment, 
enzyme stability or formation of mutant-normal heterodimers (Roberts et al. 1998). 
The consequences of PPOX mutations have thus far been analysed only in 
prokaryotic expression systems (Meissner et al. 1996; Dailey and Dailey 1997a; 
Roberts et al. 1998). Expression studies performed in bacterial or mammalian cells may 
give controversial results due to the different localization and transport mechanisms. 
PPOX is bound to cytoplasmic membrane and coupled to the cell’s respiratory chain 
in many prokaryotes (Dailey 1990), whereas the Bacillus oxidase overexpressed in 
E. coli is soluble and includes no membrane-spanning structure (Dailey et al. 1994). 
In our series, the results from prokaryotic and eukaryotic expression systems were 
mostly in accord with one another. Only in the case of amino acid substitution P256 
did the prokaryotic expression system produce consistently lower activities relative 
to the normal allele (50%) than the eukaryotic system (100%). The transfection 
efﬁ ciency of COS-1 cells could be assessed only when the cells were transfected with 
PPOX-GFP fusion protein constructs and analysed by ﬂ uorescence microscopy. The 
efﬁ ciencies were constantly less than 10% with both chloroquine-CaCl
2
 precipitation 
and Fugene6 lipofection techniques. Since the quantity of the expressed protein in 
the prokaryotic expression system is much higher than in the eukaryotic system, the 
enzyme activity assay is far more sensitive. Despite differences in cell organelles 
and transport mechanisms, we believe that the prokaryotic expression system is 
sufﬁ ciently reliable for analysing the effect of a single nucleotide change on enzyme 
function in humans.
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1.2.3. Reduced levels of  mRNA transcripts
The mutation 338G→C showed a dramatic decrease in the steady-state level 
of the mutant transcript in the patient’s lymphocytes compared with that of the 
normal allele. This is consistent with previous ﬁ ndings in which several nonsense 
or frameshift mutations were associated with dramatic reductions in the steady-
state level of cytoplasmic mRNA (Cooper 1993). However, the mutations 78insC, 
R152C, 470A→C and IVS2-2a→c did not demonstrate a reduction in the mRNA 
level at steady state. This was unexpected since the mutation IVS2-2a→c produces a 
termination codon near the 5’ end of the gene, and normally, the closer a termination 
codon is to the 5’ end of the gene, the lower the level of mRNA transcripts is likely 
to be (Cooper 1993). The mechanisms of how premature termination codons reduce 
mutant mRNA levels are not yet known. Because the rate of gene transcription is 
not decreased (Urlaub et al. 1989; Cheng and Maquat 1993), mRNA decay must 
take place in the translation phase. It was anticipated that the decay would occur 
in the cytoplasm, where the ribosomes would scan the transcript and recognize the 
termination codon, initiating the down-regulation of mutant mRNA (Urlaub et al. 
1989; Carter et al. 1996). A model in which the mRNA decay is a nuclear event has 
also been proposed (Urlaub et al. 1989). 
1.2.4. Mitochondrial transport of  PPOX
The mitochondrial targeting signal was localized in the 28 amino acids in the amino-
terminal end of PPOX. The predicted secondary structure of the PPOX amino-
terminus consists of a βαβ-motif (Nishimura et al. 1995) that contains an α-helix, 
which is a common structure found in mitochondrial targeting signals. Our structural 
model of the  interaction between the amino-terminus of PPOX and Tom20 and 
the experiments with amino-terminally mutated fusion proteins indicated that the 
critical residues for recognition of the PPOX targeting signal include leucine and 
isoleucine residues that form a hydrophobic motif LXXXIXXL. Our ﬁ ndings support 
the hypothesis that recognition of the mitochondrial targeting signal is dependent 
on hydrophobic interactions with the mitochondrial receptor. The NMR structure of 
rat Tom20 in a complex with the mitochondrial presequence peptide revealed that 
an amphiphilic α-helical structure of the presequences was important for binding 
to the receptor (Abe et al. 2000). Subsequent mutagenesis studies showed that the 
hydrophobic residues were essential for binding to Tom20, while the hydrophilic 
residues, including two positively charged arginines in the presequence, were 
dispensable (Abe et al. 2000). Replacing a single hydrophobic leucine or isoleucine 
in the amino-terminal recognition sequence of PPOX with a hydrophilic residue of 
the same size consistently prevented the mitochondrial transport. 
The amino terminus of PPOX contains only three positively charged residues, 
which is less than in most presequences (Tzschoppe et al. 2000). It has been postulated 
that the positively charged residues could be involved in subsequent ionic interactions 
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between the targeting signal and Tom22, which is also known to bind amino-terminal 
recognition sequences, especially their carboxyl-terminal parts, in a salt-sensitive 
manner (Brix et al. 1997, 1999). In the case of PPOX, two positively charged residues 
Arg23 and Lys29 located in the carboxyl-terminal part of the recognition sequence, 
could facilitate this interaction.
Surprisingly, PPOX derivatives where the amino-terminal targeting signal was 
removed either totally or partially were still located in the mitochondria. This implies 
that the residual part of PPOX must contain an additional mitochondrial targeting 
signal(s) (Tzschoppe et al. 2000). PPOX is a further example of mitochondrial 
proteins whose import is not strictly dependent on the presence of an amino-terminal 
presequence (Michaelis et al. 1991; DeLabre et al. 1999; Krause-Buchholz et al. 
2000; Tzschoppe et al. 2000). Secondary structure prediction of PPOX reveals several 
internal leucine-rich α-helical segments with a net positive charge (Figure 16). Such 
segments can putatively form hairpin-like structures that mimic a typical amphiphilic 
presequence and function as an internal mitochondrial targeting sequence (Folsch 
et al. 1998). Without knowledge of the tertiary structure of PPOX, it is, however, 
difﬁ cult to predict which of these segments is accessible to the receptor and serves as 
an effective targeting signal.
2. Clinical and biochemical features and pathogenetic mecha-
nisms of  VP
2.1. Acute attacks and photosensitivity  different pathogenetic mech-
anisms?
Our series includes both patients with symptoms (52%) and phenotypically normal 
carriers (48%), thus providing information about the clinical and biochemical outcome 
among VP patients in general. The proportion of patients with acute attacks (27%) 
in this series is somewhat lower than in some extensive family studies, in which up 
to 38% of patients had experienced acute attacks (Eales et al. 1980; Whatley et al. 
1999), but higher than the 4-15% recently reported for a large South African kindred 
(R. Hift, personal communication). The frequency of photosensitivity in our series 
(40%) is lower than reported previously in South Africa and France (70%) (Eales et 
al. 1980; Whatley et al. 1999), but comparable with that of the recent South African 
study (39%) (R. Hift, personal communication). Extended mutation screening among 
symptom-free family members and improved counselling explain the differences in 
these numbers.
Since only 26% of symptomatic patients suffered both photosensitivity and acute 
attacks, the majority of the patients with each of these manifestations were in two 
distinct groups. This is in line with other studies, where 79% and 77% of symptomatic 
patients experienced either photosensitivity or acute attacks, but not both (Eales et 
al. 1980; Whatley et al. 1999). We have shown that the occurrence of acute attacks 
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has decreased markedly during the last two decades, whereas no such tendency has 
been observed for skin symptoms (Timonen et al. 1990b; Kauppinen and Mustajoki 
1992). The decrease has been more prominent in males since they are not prone to 
cyclical factors. This indicates that different pathogenetic mechanisms may underlie 
the development of skin symptoms and acute attacks. The latter may be more readily 
prevented by avoiding precipitating factors. 
The occurrence of skin symptoms was related to a more than 4-fold increase in 
urinary copro- and uroporphyrin excretion. In contrast, normal faecal protoporphyrin 
excretion as well as negative plasma ﬂ uorescence predicted freedom from skin 
symptoms. These ﬁ ndings support the theory that the severity of chronic skin 
symptoms is likely to depend on the permanent circulating levels of uro- and 
coproporphyrins (Day 1986; Timonen et al. 1990b). In the pathogenesis of acute 
attacks, the direct or indirect induction of ALAS, which is the rate-limiting enzyme 
of the pathway, plays a key role. ALAS induction leads to a transient increase of 
circulating porphyrin precursors ALA and PBG, which could be responsible for the 
neurological manifestations during an acute attack (Meyer et al. 1998).
2.2. Genotype-phenotype correlation and modifying genetic factors
Since patients with the I12T mutation experienced no photosensitivity and acute 
attacks were rare, a correlation could be made between the PPOX genotype and 
phenotype. In addition, biochemical abnormalities were milder, suggesting a less 
severe form of the disease in patients with the I12T mutation than in those with 
other mutations. No such correlation could be demonstrated in another study of 100 
families, where the relationship between mode of presentation (skin lesions alone, 
acute attack alone, or both together) and type of mutation (nonsense or frameshift, 
missense or splice site) was studied (Whatley et al. 1999). Our results show that 
pooling of mutations should be avoided since the effect of the mutation on enzyme 
function is often difﬁ cult to predict and genotype-phenotype relationships within 
the subgroups can go undetected. Detailed phenotyping of all symptomatic and 
symptom-free patients in the families is essential and should involve the assessment 
of skin symptoms and acute attacks and relate these to the biochemical ﬁ ndings.
The milder phenotype of I12T could not be predicted by expression studies. 
The mutation lies in the highly conserved FAD-binding domain in the amino-
terminal region of the PPOX gene (Nishimura et al. 1995; Dailey and Dailey 1996), 
whereas the R152C mutation causes an amino acid substitution in exon 5 and the 
338G→C mutation results in exon 4 deletion and a truncated polypeptide. Prokaryotic 
and eukaryotic expression studies revealed a dramatic decrease in enzyme activity 
for the I12T mutation, which was comparable to the activities found in the R152C 
and 338G→C mutations. This suggests that in each mutation type post-translational 
factors and interaction between the mutant and normal polypeptide may vary and 
can modify enzyme activity in vivo, explaining the milder phenotype in patients with 
I12T. 
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The penetrance of the PPOX defect in our material was 52% (n=103), which is 
close to the 45% estimated previously by Mustajoki (1980) (n=48). The incomplete 
penetrance may be due to other modifying gene(s), such as cytochrome P450, MDR2 
or MRP1, which could modify porphyrin metabolism in the liver and the permanent 
level of circulating porphyrins predisposing to skin symptoms. Alternatively, 
environmental inﬂ uences may modify the phenotype, especially in relation to acute 
attacks, which may be provoked by several exogenous factors.  
2.3. Homozygous variegate porphyria
The clinical and biochemical ﬁ ndings in our patient are consistent with earlier 
reported cases of homozygous VP. The CNS involvement with minor motor co-
ordination disturbances and slight verbal and visuospatial deﬁ ciencies seems to be 
weaker than in half of the cases where patients suffer from mental retardation. This 
implies that considerable variation may exist in the homozygous VP phenotype. 
Severe photosensitivity with early onset in childhood is common in all reported 
cases, as are mild developmental abnormalities, suggesting that certain early stages 
of development may be critically dependent on heme biosynthesis (Roberts et al. 
1998). During the 20-year follow up no signs of acute attacks were observed in our 
patient. This is in accordance with previous reports, where only two of the 14 known 
homozygous patients had experienced such attacks (Coakley et al. 1990; Corrigall 
et al. 2000). This implies that factors other than the absolute level of PPOX may be 
important in the aetiology of acute attacks (Palmer et al. 2001).
In homozygous VP, at least one of the mutations in the PPOX must have substantial 
residual activity, otherwise heme biosynthesis would not be possible and the patient 
could not survive. This is probably the case with the South African mutation R59W 
since no homozygous patients have been encountered despite the high prevalence of 
the mutation (Meissner et al. 1996; Warnich et al. 1996). This is compatible with our 
ﬁ ndings that in heterozygous patients the I12T mutation causes a signiﬁ cantly milder 
clinical phenotype than in other patients. Without the homozygous patient in the 
family, all heterozygous patients would have remained undiagnosed.
In the previously reported mutations in homozygous VP patients, 10-25% residual 
activity was observed in prokaryotic expression systems (Dailey and Dailey 1997a; 
Roberts et al. 1998), which is slightly more than observed for the I12T mutation (0% 
in E. coli and 8% in COS-1 cells). Unlike these mutations, the I12T mutation resides 
in the conserved amino-terminal part of PPOX (Figure 16) and could cause the disease 
by a different mechanism, such as disruption of mitochondrial transport or FAD 
binding (Nishimura et al. 1995). However, our study showed that riboﬂ avin treatment 
could not restore enzyme activity in vitro or alleviate clinical manifestations. While 
the mutation was able to disrupt the amino-terminal mitochondrial transport of the 
truncated PPOX, the corresponding full-length PPOX was nevertheless transported 
into mitochondria. It would be intriguing to hypothesize that in this patient the 
secondary mitochondrial targeting signal(s) could serve as a backup system, which 
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directs the peptide into mitochondria if the primary signal fails. This transport may, 
however, be less speciﬁ c and efﬁ cient (Zara et al. 1992) and lead to non-optimal 
submitochondrial compartmentalization. This could explain the 10% residual activity 
in vivo measured from the patient’s lymphocytes, which is sufﬁ cient for him to 
survive.
Non-optimal association of the I12T polypeptide with the mitochondrial 
membranes could disrupt the ﬁ nal steps of heme biosynthesis in the inner 
mitochondrial membrane, especially if substrate channelling between the last three 
enzymes of the pathway, coproporphyrinogen oxidase, PPOX and ferrochelatase, 
occurs through an enzyme complex, as suggested by Ferreira et al. (1988). Disruption 
of the enzyme complex could explain the low ferrochelatase activity measured from 
homozygous and heterozygous patients’ erythrocytes, 10% and 30-40% of normal 
activity, respectively (R. Kauppinen, personal communication). Low ferrochelatase 
activity with elevated zinc protoporphyrin concentration in erythrocytes has also been 
reported in other cases of homozygous VP (Kordac et al. 1985; Murphy et al. 1986).
3. Diagnostics of  VP
Conventional assays of urinary and faecal porphyrins detect only about 70% of VP 
patients; thus a large number of latent cases remain undetected. The identiﬁ cation 
of PPOX mutations in the Finnish VP families now facilitates reliable DNA-
based diagnostics in each family. If a patient belongs to a known VP family, the 
mutation analysis is reliable and easy to perform. In families, where the mutation 
is unknown, the value of DNA analysis is reduced. Mutations can be detected using 
various DNA techniques, which can be chosen according to the experience of the 
laboratory personnel. In asymptomatic patients, DNA analysis alone is sufﬁ cient for 
the diagnosis of VP, whereas in symptomatic patients a proper clinical investigation, 
detailed family history and biochemical measurements should be conducted before 
the diagnosis is conﬁ rmed. 
During an acute attack the measurement of urinary porphobilinogen and delta-
aminolevulinic acid is the method of choice, and measurements of plasma ﬂ uorescence 
and faecal protoporphyrins are useful in distinguishing VP from other acute porphyrias 
(AIP and hepatic coproporphyria). If a patient experiences photosensitivity, 
plasma ﬂ uorescence, urinary copro- and uroporphyrin and faecal protoporphyrin 
measurements are essential and distinguish VP from other cutaneous porphyrias 
(porphyria cutanea tarda, hepatic coproporphyria, erythropoietic protoporphyria, 
congenital erythropoietic protoporphyria) (Mustajoki 1980; Poh-Fitzpatrick 1980; 
Timonen et al. 1990b). The assay for lymphocyte protoporphyrinogen oxidase is 
technically laborious but may provide additional information if other biochemical 
analyses remain inconclusive. In each case, the diagnosis of VP should be conﬁ rmed 
using DNA analysis whenever possible, and mutation screening is indicated for 
family members.
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This work describes the molecular genetics of VP in Finland. The main results are 
summarized as follows:
• Eight mutations, including three amino acid substitutions, an insertion and three 
splicing defects, were identiﬁ ed among Finnish VP families. A founder mutation, 
R152C, was detected in 11 families. 
• The outcomes of seven mutations were studied by ampliﬁ cation and sequencing 
of the reverse-transcribed total RNA obtained from patients’ EBV transformed 
lymphoblast cell lines. One of the mutations (338G→C) showed a decrease of the 
steady-state level of the mutant transcript in the patient’s lymphocytes compared 
with that of the normal allele. No reduction in mRNA level could be demonstrated 
for the other six mutations studied. 
• The normal and ﬁ ve mutant polypeptides were expressed in E. coli and in 
COS-1 cells. Enzyme activities of all mutated alleles (78insC, IVS2-2a→c, 
338G→C, R152C and 470A→C) were decreased to 0-5% of wild-type activity in 
both cell types, conﬁ rming the causality of the mutations and enzymatic defects in 
the disease.
• The mitochondrial targeting signal was localized in the 28 amino acids in the 
amino-terminal end of PPOX. Amino acids 25-477 of PPOX contain at least one 
mitochondrial targeting signal in addition to the amino-terminal signal.
• Of the 103 Finnish VP patients diagnosed between 1966 and 2001, 40% had 
photosensitivity, 27% acute attacks and 14% both manifestations. Acute attacks 
have decreased dramatically from 38% to 14% in patients diagnosed before and 
after 1980, whereas the prevalence of skin symptoms has decreased only subtly 
from 45% to 34%. 
• Patients with the I12T mutation experienced no photosensitivity and acute 
attacks were rare (8%). The occurrence of photosensitivity was therefore lower 
in the I12T group than in the R152C group (p=0.001), whereas no signiﬁ cant 
differences between the R152C and 338G→C groups were observed. Biochemical 
abnormalities were also signiﬁ cantly milder in patients with the I12T mutation.
• Normal excretion of protoporphyrin in faeces in adulthood predicted freedom from 
both skin symptoms and acute attacks. All patients with urinary coproporphyrin 
excretion exceeding 1000 nmol/d experienced skin symptoms, acute attacks, or 
both.
• DNA diagnostics of VP was developed for 20 of the 22 known Finnish VP families 
in which the mutation was detected.
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